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Abstract
The pathogenesis of infectious kidney stones is poorly understood, while equally
unclear is the role of urinary modulators and bacteria. An experimental model was
created and utilized to test a variety of urinary modulators and bacterial strains commonly
associated with struvite and calcium phosphate stones to evaluate their potential roles in
influencing crystal formation. Modulators such as acids, citrate, and osteopontin had
strong inhibitory effects on infectious crystal formation while the remaining modulators
had neutral, mixed, inhibitory, or enhancing effects. Lastly, it was determined that the
presence of urease may not directly lead to calcium phosphate and struvite stones in all
cases, and in the absence of urease, bacteria may promote calcium phosphate stone
formation. Ultimately, this model will help to provide researchers with the ability to
rapidly test a wider range of urinary modulators with infectious kidney stone formation
and how they relate to individual bacterial species.
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Summary for Lay Audience
Kidney stones will affect about 10-11% of the population at some point during
their lifetime and that rate appears to be increasing. As this is a common condition, it has
a significant financial impact on the healthcare system. There are different types of
kidney stones, but only two associated with urinary tract infections, struvite and calcium
phosphate stones. Struvite and calcium phosphate stones represent about 10-15% of
stones in patients, however, their clinical importance cannot be understated. The
occurrence of these stones can lead to recurrent infections, sepsis, and even death. They
also tend to have a higher recurrence rate than the more common calcium oxalate stones
and typically require surgical management.
Researchers’ understanding of kidney stone development has improved over
recent history, but a lot is still yet to be uncovered. One question that eludes researchers
is how certain stones commonly associated with urinary tract infections, such as calcium
phosphate, can form even in the absence of an infection. Furthermore, researchers believe
there must be more to the equation in understanding how struvite or calcium phosphate
stones can form even in the presence of an infection. Several proteins and substances in
the urine are thought to play a role in the development of these stones and discovering
their mechanism will have major clinical implications. Using a novel high-throughput
laboratory model with artificial urine, the following document outlines our approach in
testing a high number of these modulators and select bacterial strains to see their effect on
infectious stone formation.
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Chapter 1
1

Introduction

The first identified urinary stone was found in the bladder of a 4500-year-old
Egyptian mummy by the English archeologist Smith.1 Detailed documentation describing
the treatment of urinary stones goes back over 1500 years.1 The late 18th century saw a
rise in interest within the scientific community regarding the composition of urinary
stones and their etiologies.2 It is no surprise that the origins of urinary stone study can be
traced back this far given that urinary stones kidney stones (nephrolithiasis) are a
common condition that affects around 10-11% of people during their lifetime.3–5 While
not typically a fatal condition, significant morbidity including sepsis and chronic kidney
disease can occur. Furthermore, kidney stone patients have been shown to have a lower
quality of life compared to those without stones6 owing to frequent emergency room
visits for acute renal colic and the possible need for surgery. Due to the prevalence of
kidney stones and extensive medical resource use, the United States alone saw the cost of
kidney stones to health care rise 50% from 1994 to almost $2.1 billion dollars in 2000.7
Not only are kidney stones prevalent, but they can be a recurrent condition.
Without any intervention there is a 50% chance of developing another stone within 10
years for all stone formers.8 However, the likelihood of recurrence can rise to 60-75% (or
greater) in some patients depending on their stone type, urinary/metabolic abnormalities,
or other environmental factors.9,10 Therefore, there is a major clinical focus on evaluating
these patients and initiating lifestyle modifications or pharmacotherapies to minimize the
risk of recurrence. Dietary modifications and appropriate medical management are
examples of methods to reduce stone recurrence rate11 yet despite the moderate success
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with these clinical approaches, there is still a significant amount that we do not
understand regarding the pathogenesis of urinary stone disease.12,13 Even more evident, is
the lack of pathophysiologic understanding in infectious urinary stones and a paucity of
preventative strategies with a proven track record of clinical benefit. Patients with
infectious-based stones are a serious burden to the health care system because of the
stone recurrence rate, recurrent infections, sepsis, and the higher rate of surgical
intervention. A better understanding of the mechanisms behind infectious stone formation
and more reliable prevention of their occurrence, may lead to improvement in patient care
and quality of life.

3

1.1

Epidemiology of urolithiasis

The lifetime prevalence of kidney stones has been approximately 10%3,5 but a
more recent update to the National Health and Nutrition Examination Survey (NHANES)
shows that the prevalence has increased to 11% in the US.4 The incidence of kidney
stones has also been increasing over time with the most contemporary data at 2.1%4
which has increased since a review of US patients from 2005-2015 showing a 1%
incidence rate.3 Historically, it was thought that the ratio between males and females was
3:1, however the gender gap has been closing. The NHANES in the United States from
2007-2010 showed that the prevalence of stones in males was 10.6% compared to 7.1%
in females, with the overall prevalence being markedly higher compared to the NHANES
III study from 1988-1994.14 However, in 2015, Tundo et al. found that stone formers in
the US were approximately 52% male and 48% female3 and the most updated NHANES
data shows relative risk of stones between sexes is not significantly different.4 The
increase in stone incidence is being demonstrated in both males and females.15
The average age of stone formers is 47 years for males and 45 years for females.16
The prevalence of kidney stones, for both males and females, increases as people get
older.5,14 For example, the prevalence in males and females over the age of 70 is 18.8%
and 9.4%, respectively.14 Non-Hispanic Whites (10.3%) have the highest prevalence of
stones compared to Hispanics (6.4%) and non-Hispanic Blacks (4.3%).14 While the
difference for this is not clear, diet and environmental factors could be associated. In
regards to environmental factors, higher rates of stone formation have been shown in
warmer climates9 such as in the Middle East, where stone prevalence has been reported to
be between 20-25%.17 The most likely cause for this finding is dehydration from excess
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sweating with a further possibility of limited access to water. Areas with seasonal
variation have also supported this claim with an increase of stones in the warmer months
of the year,17 however, this has not been consistently demonstrated in the literature.18
Furthermore, there tends to be a higher risk of developing stones in the Western
hemisphere (5-15%) compared to the Eastern hemisphere (1-5%).19
A family history of stones can also be a significant predictor for developing
kidney stones and can be identified in 34% of stone patients.16 A study by Curhan et al.
observing family history in a group of all male participants demonstrated someone with a
first-degree relative with a stone was 2.6 times more likely to develop urolithiasis. The
familial relationship was also stronger when the stone patient was younger than 60.20
Genetic or familial inheritance has also been investigated with a twin registry, which
showed a 56% inheritability of stones based on a genetic model.21
As stated earlier, the cost of kidney stones to health care in the US was almost
$2.1 billion dollars in 2001, an increase of 50% from 1994.7 There are estimates that this
number could balloon to $4.1 billion dollars by 2030.22 The costs associated with kidney
stone disease relies on a number of factors including emergency room visits, outpatient
visits, admissions to hospital, surgery, medications/prescriptions, and other indirect costs.
Acute renal colic leads to more than 1.3 million visits to the emergency department per
year in the United States.22 However, these numbers are likely inflated by patients
returning to the emergency department multiple times. Over 10% of patients with kidney
stones will likely return to the emergency department within 30 days and about one third
of those patients will undergo urgent intervention. The number of emergency room and
outpatient visits for patients with kidney stones has been increased by 50% and 40%,
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respectively. In a 25-year-long study by Johnson et al., it was found that 44% of patients
with an obstructing stone will eventually be admitted to hospital.18 When admission is
required, the typical length of stay is 2.2 days for all patients, but increases to 4.4 days for
patients over 80 years old.7 Overall, the funding required to take care of kidney stone
patients is staggering and it appears that kidney stone disease will increasingly burden the
healthcare system without the implementation of robust preventative strategies.
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1.2

Clinical presentation of urolithiasis

Patients presenting with a kidney stone will typically have pain that will usually
originate from the flank, but can also radiate to the ipsilateral abdomen, groin, testicle, or
labia. The pain often will have an abrupt onset and can last anywhere from 15 minutes to
several hours with fluctuating severity. Acute renal colic is caused by obstruction of the
urinary tract and distension of the renal capsule. There can also be associated nausea and
vomiting due to the shared innervation with the celiac plexus between the kidney and
bowels.23 It is important to take a careful history to delineate the origin of the symptoms
because there can be overlap between renal colic and other painful conditions within the
abdomen and pelvis. Additional symptoms include hematuria, dysuria, urinary urgency,
and urinary frequency. If the working diagnosis is renal colic, then imaging (plain film Xray, ultrasound, or computerized tomography) is performed to confirm the diagnosis. It is
possible for patients to be asymptomatic with an obstructing stone, but this is uncommon.
Urolithiasis can be picked up incidentally on imaging and this is usually associated with
non-obstructing caliceal stones.
In a patient with an obstructing stone and a normal contralateral kidney, there is
typically no renal dysfunction present. However, an obstructing stone in a patient with a
solitary kidney or bilateral obstructing stones can lead to acute kidney injury and even
renal failure. Another important clinical presentation is an obstructing stone in the
presence of infection which can lead to sepsis and even death. Evaluating the patient’s
vital signs, serum leukocytes, urinalysis and urine culture can help determine if the
patient has an active urinary tract infection (UTI). Both clinical scenarios require urgent
renal drainage and broad-spectrum antibiotics are required in the presence of infection.
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1.3

Pathogenesis of urolithiasis

Kidney stones are made up of urinary salts and other macromolecules. A salt
placed in solution can be dissolved up to a certain concentration which is referred to as
the saturation point.24 These phase changes are determined by the supersaturation in
solution, which is the ratio of the concentration of these salts to their solubilities.25 This
has been considered the most important factor in stone formation for over 50 years
because without being above supersaturation, no stone could ever be formed.26 Urine is
typically metastable so that it can handle an increased concentration of salts, however
there is an upper threshold that when surpassed will lead to crystallization of the salts out
of solution.27
If the supersaturation exceeds the solubility, then the dissolved free ions form
solids in a process called nucleation, which typically occurs on an existing surface. In
vivo, the possible surfaces on which this can occur include cell debris, urinary casts,
epithelium, collecting ducts, and other crystals.17,28 Once nucleation has occurred and is
fixed in the urinary collecting system, crystals can materialize more easily compared to
forming the initial nucleus.24 Aggregation is a term to describe amalgamation of crystals
in solution that lead to multiple individuals components coming together to make a larger
solid. Crystal growth occurs when ions move directly out of solution and solidify to
increase the size of one crystal.27 Crystal retention is another mechanistic theory for stone
growth, which occurs when a crystal is physically stuck or the movement of the particle
is slower than the flow of urine.26
While it plays a prominent role, supersaturation of salt ions is not the whole
equation in stone formation. There is a complex interplay between other factors including
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urinary pH, urinary modulators, genetics, and urinary milieu that can lead to stone
formation, growth, or inhibition. A longstanding theory for the pathogenesis of calcium
oxalate stones was the initial formation of Randall’s plaques. These plaques begin in the
thin loop of Henle and are composed of apatite (calcium phosphate) crystals. Calcium
oxalate stones then form on the outer surface of these plaques because they are stable and
decrease the threshold to crystalize out of solution.25 Altering urinary pH can lead to
changes in the supersaturation of urinary salts and can also promote certain types of
stones to form (low pH = uric acid stones, high pH = struvite or calcium phosphate
stones). Urinary modulators can be broken down into promoters and inhibitors of crystal
formation. Some promoters include low urine volume, bacterial products and urate27,28
while some inhibitors include magnesium, pyrophosphate, Tamm-Horsfall protein
(THP), urinary prothrombin fragment-1 (UPTF-1), glycosaminoglycans (GAG), citrate,
osteopontin (OPN), nephrocalcin, lipids, inter--inhibitors (II) and hyaluronic acid
(HA).24,27,28
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1.4

Composition of urolithiasis

Calcium oxalate stones account for approximately 60-75% of all urinary stones
and can be further subclassified into monohydrate (whewellite) and dihydrate
(weddellite) forms.17,29 Under the microscope, the crystal’s shape for calcium oxalate
monohydrate is similar to “dumbbell” while calcium oxalate dihydrate has a more
tetragonal “envelope” appearance. Calcium phosphate can also be subdivided into apatite
(Ca10[PO4]6[OH]2) and brushite (CaHPO4·2H2O). Amorphous shards are the typical
appearance of calcium phosphate crystals. Calcium phosphate stones can either be pure
or, more commonly, they are mixed with calcium oxalate. The standard nomenclature
assigns the stone type based on the most predominant crystal (i.e., >50% calcium oxalate
or calcium phosphate) found within the makeup of the stone.
The remaining non-calcium-based stone types include uric acid, struvite and
cystine stones. Uric acid stones are the second most common non-calcium stone and have
an appearance similar to “barrels, rhomboids, or needles.” Struvite (MgNH4PO4·2H2O)
stones, which are classically associated with infections and not necessarily a metabolic
abnormality, have the appearance of a “coffin-lid.” Cystine stones are caused by a rare
genetic abnormality and the crystal appearance is a “hexagonal” shape. There are also
other rare types of stones that can be related to medications including: magnesium
trisilicate, ciprofloxacin, sulphonamides, triamterene, indinavir and ceftriaxone.17
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Table 1: Stone type and occurrence rate.12,29
Crystal Type
Calcium oxalate

Occurrence (%)
60%

Calcium phosphate

20-25%

Uric acid

5-10%

Struvite

5-10%

Cystine

1-3%

Other

< 1%

1.4.1

Calcium oxalate stone formation
As indicated above, there can be two formulations of calcium oxalate stones:

monohydrate (whewellite) and dihydrate (weddellite). These stones are thought to
originate on Randall’s plaques.17 Low urinary volume, hypercalciuria, hyperoxaluria,
hypocitraturia, or lack of stone inhibitors can lead to calcium oxalate stone formation.
Low urine volume is a very common metabolic issue ranging from 38-70% in
stone formers11,27,30 which leads to higher urinary supersaturation of calcium oxalate and
subsequent stone development. However, this can be further exacerbated if the urinary
concentration of calcium and/or oxalate are elevated. Dehydration is not solely a calcium
oxalate stone issue but is pervasive in many stone formers.
While not consistent across all studies,11 hypercalciuria is generally thought of as
the most common metabolic abnormality identified in a stone metabolic workup. For
calcium-based stone disease, some see it as the most significant pathophysiologic
variable12 with an overall prevalence varying from 25-60% of stone formers.27
Hypercalciuria is typically idiopathic and can originate from defects in the kidney (renal
leak), gut (absorptive), and bone (resorptive).12 Further causes can also be from primary
hyperparathyroidism, sarcoidosis, malignancy, immobilisation, granulomatous disease,
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use of carbonic anhydrase inhibitors, and milk-alkali syndrome.27,28 Acid load from a
high animal protein diet can increase urinary calcium by stimulating bone loss and
reducing renal tubular absorption of calcium.31 Not only does protein increase excretion
of urinary calcium, but also decreases excretion of urinary citrate.32 Thus, it is not
surprising that increased purine load from animal protein leads to more kidney stones.33
There is a significant association between increased dietary sodium intake and elevated
urinary calcium in stone formers and non-stone formers which should also be considered
when evaluating idiopathic hypercalciuria.34
Consumption of dietary oxalate comprises anywhere from 10-50% of oxalate
filtered in the urine.35 Foods that are typically higher in oxalates are teas, nuts, beans,
green leafy vegetables, rhubarb, coffee and chocolates. The majority of oxalate within the
body comes from endogenous sources like the liver or metabolism of vitamin C.
Hyperoxaluria can occur from excessive dietary intake, intestinal disorders, gastric
bypass surgery, prior bowel resection or genetic disorders.27 Primary hyperoxaluria is a
genetic condition that has three types with variable clinical presentations due to different
errors in the oxalate metabolic pathway. Primary hyperoxaluria type 1 is the most
significant because it presents at a young age and can lead to kidney failure. In addition,
certain bacteria within the gut degrade oxalate and prevent it from building up in the
urine. Oxalobacter formigenes is one of the more common species found in the gut that
can degrade oxalate. Persistent antibiotic use can disrupt the bowel microbiome leading
to increase uptake of oxalate and development of calcium oxalate stone disease.36
Citrate can form a highly soluble complex with calcium and acts as inhibitor of
stone formation by interfering with crystallization.28 Acidosis is a major cause of
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hypocitraturia and can occur in 20-60% of stone patients. Other causes of hypocitraturia
include distal renal tubular acidosis (dRTA), chronic diarrhea, hypokalemia, physical
exercise and a diet rich in animal protein.37 Hyperuricosuria can also promote calcium
oxalate formation because sodium urate can initiate calcium oxalate crystallization in the
background of calcium oxalate supersaturation leading to heterogenous nucleation.12
Causes of hyperuricosuria are excess dietary purine intake, gout, myeloproliferative
disorders, tumour lysis syndrome, and Lesch-Nyhan syndrome.28

1.4.2

Uric acid stone formation
There are three factors involved in uric acid stone formation including low urine

volume, acidic urine, and hyperuricosuria. The most important factor for uric stone
formation is urinary pH. At a urinary pH of 5.5, uric acid is in equilibrium with urate, but
when the pH drops below 5.5, it leads to undissociated uric acid and crystal
precipitation.12 Uric acid stones can form in the absence of hyperuricosuria if the pH is
low enough because uric acid has very low solubility when compared to urate.
Hyperuricosuria can be caused by increased purine catabolism, increased endogenous
uric acid production (i.e., gout), consumption of a purine rich diet or chronic diarrhea.
Individuals with metabolic syndrome (hypertension, diabetes, obesity and/or
hyperlipidemia) have consistently shown to be at a higher risk of stone development, but
they tend to have higher rates of uric acid stones compared to other stone formers as the
urinary pH declines with increasing bodyweight.17,25 The presumed mechanism of uric
acid stone formation in metabolic syndrome is insulin resistance and impaired ammonium
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excretion leading to lower urinary pH.12 Uric acid calculi make up 34% of stones in
patients with diabetes but only 6% of those patients without.38

1.4.3

Infectious stone formation
In contrast to other stones, infectious stones are not necessarily associated with

any metabolic abnormalities and can be a result of the urinary environment leading to
bacterial proliferation and alkaline urine. The two types of infectious stones are struvite
and calcium phosphate. Struvite is associated with UTIs with urease producing bacteria
(Klebsiella species (sp), some Proteus sp, some Pseudomonal sp, etc.). Urease reacts with
urea to create ammonia and carbon dioxide, which raises the urine pH. UTIs can be seen
in 33.3% of patients with only calcium phosphate stones, but the percentage increases to
73.1% if you include apatite and struvite stone composition. Calcium phosphate stones
can also occur in the absence of infection and can be associated with specific conditions,
namely dRTA and primary hyperparathyroidism (PHPT). Distal RTA patients develop
hypokalemia and acidosis due to the kidneys inability to excrete protons, which leads to
persistently alkaline urine and hypocitraturia. Primary hyperparathyroidism occurs due to
excessive excretion of parathyroid hormone (PTH) from the parathyroid gland leading to
hypercalcemia.
Two hypotheses have been proposed to explain why calcium phosphate stones
form in the absence of clinical infection and without any struvite component. The first
theory is that a clinically asymptomatic UTI was responsible for the stone formation.10
The second theory is that an infectious process was involved in the initial steps of the
stone formation and disappeared secondarily.10 However, neither of these theories have
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been scientifically validated and the scientific community remains largely unfamiliar with
the pathogenesis of calcium phosphate stones.
In their review of 39 patients with calcium phosphate stones, Carpentier et al.
showed that three of the stones analyzed had bacterial imprints without any history of
UTI and 24 out of 39 patients with calcium phosphate stones had hypercalciuria.39
Although we have typically focused on pH levels with struvite stone formation, calcium
phosphate crystallization has been shown to be more sensitive to pH changes compared to
struvite.39 This could explain why calcium phosphate stones form instead as struvite
crystallization requires a high magnesium ammonium phosphate molar product, which is
not always found in infected urine.39,40

15
Table 2: Urease producing organisms.29
Organisms
Usually (>90% of isolate)
Gram-negative

Gram positive

Mycoplasma
Yeast

1.4.4

Proteus rettgeri
Proteus vulgaris
Proteus mirabilis
Proteus morganii
Providencia stuartii
Haemophilus influenzae
Bordetella pertussis
Bacteroides corrodens
Yersinia enterocolitica
Brucella species
Flavobacterium species
Staphylococcus aureus
Micrococcus
Corynebacterium ulcerans
Corynebacterium renale
Corynebacterium ovis
Corynebacterium hofmannii

Occasionally (5-30% of
isolates)
Klebsiella pneumoniae
Klebsiella oxytoca
Serratia marcescens
Haemophilus parainfluenzae
Bordetella bronchiseptica
Aeromonas hydrophila
Pseudomonas aeruginosa
Pasteurella species

Staphylococcus epidermidis
Bacillus species
Corynebacterium murium
Corynebacterium equi
Peptococcus asaccharolyticus
Clostridium tetani
Mycobacterium rhodochrous
group

T-strain Mycoplasma
Ureaplasma urealyticum
Cryptococus
Rhodotorula
Sporobolomyces
Candida humicola
Trichosporon cutaneum

Cystine stone formation
Cystine stones typically present in individuals with a strong family history or a

personal history of stones during childhood. While patients can have 100% cystine
stones, generally more than half of cystine stones have mixed composition due to other
physiological abnormalities putting them at risk for other stone types.28 The basis of
cystine stone formation is genetically inherited defects in renal transport. Originally, the
inheritance pattern was thought to be autosomal recessive, but there are heterozygotes
and even autosomal dominance patterns with incomplete penetrance leading to variable
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clinical presentations.17 A heavy chain subunit rBAT (SLC3A1 gene mutation) and the
light subunit b0,+AT (SLC7A9 gene mutation) of the amino acid transporter interact with
each other at the brush border of the proximal renal tubule. Defects in either component
can clinically present with cystinuria and can be categorized as type A or B, respectively
(also known as cystinuria type I or cystinuria type II). These subtypes are clinically
indistinguishable and have the same standards for diagnosis.25 These genetic mutations
prevent the kidney from being able to reabsorb the amino acids ornithine, arginine, lysine
and cystine (oxidized dimer form of cysteine). The excessive excretion of cysteine from
the kidney and its lower solubility in water leads to stone formation, while the other
amino acids can remain in solution and not cause any clinical sequelae.
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1.5

Medical management of urolithiasis

During an acute renal colic episode, the most critical step is symptom
management. If the patient can manage the initial phase of pain, it will usually settle to a
tolerable level where the patient can manage at home to either pass the stone themselves
or wait for surgical management. Non-steroidal anti-inflammatories have been shown to
be most effective for renal colic and are thus recommended to be used in conjunction
with acetaminophen to minimize narcotic use.41 Depending on the patients symptoms and
clinical presentation, antiemetics and intravenous fluids may be required. Calcium
channel blockers and alpha blockers have also been used to help facilitate passage of
stones (“medical expulsive therapy”) from the ureter, however, the clinical utility has
been debated as there may only be a mild benefit for stones over 5 mm in the distal
ureter.42,43
There is a varied approach to medically managing kidney stones based on the
stone type and metabolic abnormalities. All stone formers should have basic bloodwork
including electrolytes, calcium, creatinine, and a urinalysis as part of their initial workup
to help screen for kidney dysfunction and help rule out PHPT. General recommendations
to reduce stone recurrence include optimal fluid intake (>2 L of urine output/day),
minimizing salt intake (<2300mg/day), minimizing animal protein (<0.8-1g/kg/day),
avoiding oxalate rich foods (<100 mg/day), adding dietary citrate, and consuming a
normal amount of daily calcium (800-1000 mg/day).44 This advice can be given to all
patients that are identified to have a kidney stone and have been shown to be effective
even with metabolically active stone disease.45

18
In addition to the above-mentioned general approaches, more individualized
recommendations can be made based on the results of a metabolic stone workup and
stone analysis. A metabolic stone workup includes serum tests, spot urine and 24-hour
urine collection. See table 3 below for complete investigations included in metabolic
workup. Stone analysis should be completed whenever possible because identifying stone
type can help direct management for kidney stones. This can be especially helpful when a
full metabolic workup is not practical, or the patient is uninterested.
Indications for a metabolic stone work up include recurrent stone formers (> 1
stone event), bilateral stones, stone in a solitary functioning kidney, pediatric patient (<
18 years of age), complicated presentation (AKI, sepsis, hospitalization, etc.), patient
request/interest, family history, renal insufficiency, pure non-calcium stone former
(cystine, uric acid, struvite, etc.), pure calcium phosphate stones, patient requiring
percutaneous stone removal, systemic diseases increasing risk of stone formation (IBD,
bowel surgery, sarcoidosis, chronic diarrhea, etc.) and high risk occupation (military
personnel, pilot, police officer, etc.).29
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Table 3: Tests for metabolic stone workup with normal reference ranges.44,46,47
Serum Investigations

Normal Range for Adults

Calcium

2.2-2.57 mmol/L

Phosphate

0.81-1.62 mmol/L

Creatinine

53-106 mol/L

Bicarbonate

20-28 mmol/L

Chloride

95-105 mmol/L

Potassium

3.5-4.8 mmol/L

Uric Acid

Female: 140-360 mol/L
Male: 200-430 mol/L

Vitamin D

50-250 nmol/L

24-hour Urine Collection
pH
Volume
Creatinine

5.8-6.2
>1.5 L/day

Calcium

Female: 15-19 mg/kg/day
Male: 20-24 mg/kg/day
2.5-7.5 mmol/day

Oxalate

80-420 mol/day

Citrate

1.68-6.45 mmol/day

Uric Acid

2.5-4.5 mmol/day

Sodium

50-250 mmol/day

Potassium

20-100 mmol/day

Magnesium

2.3-4.9 mmol/day

Cystine*

< 1500 mmol/day

* Cystine only needs to be measured if there is clinical suspicion for cystinuria.
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Increasing fluid intake to address low urinary volume should be recommended in
every stone former because small daily improvements can have dramatic results. For
example, every 500 mL increase of fluid intake has been shown to significantly decrease
stone recurrence.48 A randomized trial looking at only adjusting fluid intake had an
absolute reduction in stone recurrence by 15% and that the time to recurrence was over 1
year longer compared to the control group.49 A meta-analysis and systematic review by
Fink et al. looked at secondary prevention for kidney stones and found that high fluid
intake can lead to a 60% reduction in the long term risk of kidney stone recurrence.
Exceeding 2.5 L of urinary volume per day can make the urine undersaturated for
calcium phosphate, uric acid and barely supersaturated for calcium oxalate.50
Hypercalciuria management differs from the aforementioned management
methods as its management can vary depending on the primary cause. Patients with
PHPT would also present with elevated serum calcium and PTH. This is usually
associated with a parathyroid adenoma that requires surgical removal to correct the
problem. Secondary hyperparathyroidism can be induced due to inadequate dietary
calcium absorption or low vitamin D intake. With adequate vitamin D supplementation,
serum values for vitamin D and PTH will normalize. Idiopathic hypercalciuria treatment
starts with conservative management by consuming a normal amount of calcium,
minimizing dietary salt intake and animal protein.51 High sodium intake not only
increases urinary calcium, but decreases urinary citrate and mildly elevates urinary pH.31
While consuming a low calcium diet may seem intuitive, it has been shown to increase
the risk of developing kidney stones.33,52 If hypercalciuria persists then treatment with a

21
diuretic can be considered (i.e.. hydrochlorothiazide, indapamide, and chlorthalidone),
which have been shown to decrease stone recurrence by 21.3%.53
Some argue that hyperoxaluria is more important in the formation of calcium
oxalate crystal formation because there is naturally a high calcium to oxalate molar ratio
in urine so relative increases in oxalate concentration lead to greater calcium oxalate
crystallization.54 The cornerstone of treatment for hyperoxaluria is avoiding oxalate rich
foods to minimize dietary sources. Timely calcium intake through diet or supplements
can be done with meals to chelate the oxalate in the gut and avoid absorption into the
urinary tract. Pyridoxine (Vitamin B6) is a cofactor in the alanine-glyoxylatetransaminase pathway and can decrease oxalate production. While studies have been
done which demonstrate the effectiveness of pyridoxine in decreasing stone recurrence,
there are currently no long term randomized trials supporting its use.47
As hyperuricosuria can lead to calcium oxalate stones or uric acid stones,
management will vary depending on stone type and other patient metabolic
abnormalities. Conservative strategies would be to decrease animal protein, increase fluid
intake and add dietary citrate. Treating hyperuricemia in the setting of calcium oxalate
stone disease has been successful with xanthine oxidase inhibition typically with
allopurinol. This medication works within 3 months and significantly decreases stone
recurrence by over 80%.55
Addressing hypocitraturia can be done successfully via increased dietary citrate,
minimizing animal protein or pharmacologic supplementation. Hypocitraturia is found in
up to 20% of stone formers and can be related to intestinal, renal, dietary, pharmacologic
or idiopathic causes.47 Distal RTA is a classic condition associated with hypocitraturia
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and subsequent stone formation that will typically require pharmacologic therapy.
Potassium citrate has shown not only a significant benefit for decreasing stone recurrence
in hypocitraturic patients, but also normocitraturic calcium stone formers.56,57
Uric acid stone prevention similarly focuses on a few of the lifestyle
modifications previously mentioned. Dietary modifications should focus on minimizing
animal protein, increasing fluid intake, and adding citrate. As the association between
uric acid urolithiasis and metabolic syndrome becomes stronger, there is a greater push to
focus on weight loss as part of the conservative management plan.58 If the patient is still
forming stones and pH is not reaching 6-6.5, then alkali therapy should be first line
treatment and dose adjusted accordingly.59 In pure uric acid stone formation there is not
necessarily a higher level of urinary urate so a xanthine oxidase inhibitor is reserved for
patients with concurrent gout, hyperuricosuria or failure of alkali therapy.58,60
Treating cystinuria is challenging because it requires dedication from the patient
to follow all recommendations because any small deviation from the appropriate diet can
lead to rapid stone formation. Dietary measures include aggressive hydration (3-4L of
urine volume/day while also determinedly minimizing salt intake and animal protein. If
this is not successful in avoiding stone recurrence, then the first step would be to add an
alkalinizing agent (potassium citrate) and secondly a chelating agent (tiopronin or Dpenicillamine).
Unfortunately, infection-based stones do not have an effective, durable, and safe
medical treatment to avoid stone recurrence. Acetohydroxamic acid (AHA) is a urease
inhibitor that has shown success in small studies but has a significant side effect profile
that has prevented its widespread use. Antimicrobial agents cannot fully penetrate the
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crystal lattices of the stone to treat all bacteria, so its benefit is limited once a stone has
formed.61 There are also long term-risks with prolonged antibiotic use including bacterial
resistance and secondary infections.61 Colonization of bacteria from ileal conduits,
indwelling bladder catheters, stents or patients with neurogenic bladders can lead to
impaired host defenses and infectious stone formation.62 Patients with a neurogenic
bladder can develop backflow of urine to the kidneys from elevated bladder pressures and
residual urine. Urinary stasis and refluxing urine can lead to urinary tract infections that
can lead to pyelonephritis and stone development.63 Foreign bodies, like stents and
catheters, within the urinary tract also provide an additional surface for stones to form on.
Patients requiring chronic urinary drainage with a stent or catheter tend to have more
medical comorbidities. Considering these factors, surgical management is more complex
and clinical outcomes can be suboptimal.
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1.6

Surgical management of urolithiasis

Ureteral stones less than 5 mm in size have a very high chance of spontaneous
passage (>95%), those that are 5-7 mm have about a 50% chance of passage, while stones
> 7 mm almost always require surgical intervention.25 This equates to about 20% of
patients with stones requiring surgical management.8 The three main surgical modalities
for treating stones are extracorporeal shockwave lithotripsy (SWL), ureteroscopy (URS)
and percutaneous nephrolithotomy (PCNL) where the choice of procedure depends on a
variety of clinical factors and patient preference.
SWL is an outpatient procedure that is the least invasive surgical modality. It is
usually performed under intravenous sedation but can be done with the patient fully
awake. The technique is based on using real-time imaging (fluoroscopy or ultrasound)
and an external energy source to fragment the stone in situ where after the procedure, the
patient will pass fragments spontaneously. Location of the stone, stone size, skin-to-stone
distance, renal anatomy, and stone composition all play a part in the overall success of the
treatment. Stones less than 20 mm can be offered SWL, but larger stone volumes are
associated with lower stone free rates.64 Thus, stones < 10 mm are ideal for SWL.
Brushite and cystine stones are resistant to fragmentation with SWL and should be
avoided in patients with these stone types.64 A lower pole stone location, Hounsfield units
> 1000, and a skin-to-stone distance > 10 cm yield lower stone clearance results.64
Development of ureteroscopic technology has revolutionized stone management
and has led to a migration from ESWL to URS for definitive management of renal and
ureteric calculi. Ureteroscopes today are smaller calibre and can traverse the urinary tract
all the way into the kidney with excellent visualisation. Stone treatment during URS is
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typically carried out with a holmium laser. Recommendations for ureteroscopy include
stones < 20 mm, mid or distal ureteric stones, SWL resistant stones or those unable to
undergo safe PCNL. This is an outpatient procedure that can have stone free rates up to
95% with low morbidity.65
Since the 1970s, PCNL has been used for more complex stone removal cases.66
The technique and equipment have developed over time, but it remains part of the
surgical armamentarium due to its superior stone free rates for stones larger than 20 mm.
It can also be the procedure of choice in larger (>15 mm) lower pole stones or when
retrograde access for URS may be very challenging or impossible.67 The downside with a
percutaneous approach is the increased rate of complications. Also, it may not be an
appropriate management option for some patients (significant co-morbidities, pregnant,
requiring continuous anticoagulation, etc.). Historically these patients were admitted to
hospital postoperatively, but there has been a transition towards same day discharge
especially with the use of smaller diameter tracts (i.e., miniPCNL, ultraminiPCNL and
microPCNL). In many cases there is more than one surgical option but using clinical
gestalt and having a well-informed discussion with the patient in a shared decisionmaking model will help guide the clinician to the appropriate treatment.
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1.7

Urinary modulators

Urinary modulators are compounds within the urinary system that may have a role
in the prevention and promotion of urinary stone formation. Urine pH and urinary tract
infections alter the urinary environment and can drastically affect stone formation
conditions. It is theorized that pH can affect urinary modulator effectiveness.68 Overall, it
appears there are many urinary components that play a part in crystal formation and the
search for the most impactful modulators and ideal conditions to decrease stone
formation is ongoing. Current knowledge regarding the effect of urinary pH, bacterial
pathogens, and urinary modulators will be reviewed as they relate to urolithiasis.

1.7.1

pH
Calcium phosphate crystals have been detected in vitro at pH levels starting at 6.8

and struvite only when pH exceeds 7.0. Maximal crystallization for both occurred
between pH 7.5-8.0 and the density of struvite crystals have been noted to increase at
higher pH levels.69,70 Further, increasing pH by 1.0 increases crystal aggregation 27.538%.71 Conversely with pH values below 6.0 in Griffith’s artificial urine, struvite crystals
can be completely dissolved within 24 hours and this occurs at a much more rapid rate
compared to solutions with a pH of 6.5.72 Urine at physiologic baselines can be
intermittently supersaturated with calcium phosphate, but this supersaturation is in
alkaline urine due to the conversion of bicarbonate into carbonate.73 It is clear that pH is a
driving force in the formation of infectious stones and is an important experimental and
clinical factor to consider. Prior studies have not always controlled for this variable
making it difficult to equate the results solely to the urinary modulator.
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1.7.2

Urinary tract infections
The relationship between bacteria and stones is centred around urease-splitting

bacteria and was first discovered in 1901.73 However, the majority of urinary infections
are from non-urease-splitting bacteria. Hellström in 1938 recognized the association of
urease-splitting bacteria and rapid stone formation, but he hypothesized that UTIs likely
all played a role in all stone types to varying degrees.74 When stone composition is
greater than 80% struvite/calcium phosphate then the patient’s UTI was exclusively from
a urease producing bacteria.63 In contrast, if the stone is made up of less than 20%
struvite/calcium phosphate then the urinary pathogen was most likely E. coli.63
Chutipongtanate et al. showed that calcium oxalate crystallization was significantly
increased in a dose-dependent manner with all bacteria, not just urease-splitting species,
including E. coli, K. pneumoniae, S. aureus, and S. pneumoniae.75 The stone-bacterial
relationship has been highlighted even further to show that urinary stones have their own
microbiome.76 Even after a century, we are still uncovering the full connectivity between
bacteria and stone formation, however, it has become more evident that urease-splitting
is not the only chemical reaction occurring and further research is required to obtain the
complete picture.

1.7.3

Pyrophosphate
Pyrophosphates are phosphorus oxyanions that are good at complexing metal

anions, including calcium. Pyrophosphate is present at concentrations of 15-100 M in
human urine.68 The Npt2a-/- mice model has shown increased levels of urinary
pyrophosphate and data to suggest that it acts an inhibitor of crystal nucleation.77 The
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inhibitory effect does appear to be dose dependent in vitro, but urinary excretion in stone
formers is variable. Lower pyrophosphate levels have been noted in stone formers
including a group of patients with incomplete RTA compared to normal subjects.78
However, this finding is not universally demonstrated.68
Nevertheless, therapeutic solutions have been trialed with orthophosphate therapy
and bisphosphonates (non-biodegradable pyrophosphate analogues), without clinical
success.68 Basavaraj et al. suggested that pyrophosphate has an inhibitory effect on
calcium oxalate and calcium phosphate crystallization.79 However, there is a large body
of evidence that pyrophosphate does not affect urease-induced crystallization or have any
measurable inhibitory effect on calcium oxalate or calcium phosphate crystallization.80–82
Sodium pyrophosphate has also been investigated as an inhibitor of crystallization but it
has no influence on pH changes, urease activity and bacterial growth.83 Ethane-1hydroxy-1,1-diphosphonate (EHDP) displaces previously bound pyrophosphate on
apatite crystals and has been shown to be a more effective inhibitor of apatite crystals
compared to pyrophosphate.83

1.7.4

Citrate
Most citrate is made through endogenous oxidative metabolism and it is freely

filtered through the glomerulus.79 Clinically, we know that hypocitraturia is a risk for
stone formation, and correcting this does decrease the risk of stone formation.
Concentrations of citrate in the distal and collecting ducts have been measured at 0.9
mM.68 Citrate has shown to inhibit crystal aggregation and growth at concentrations of
0.1 mM by complexing with calcium, but others have demonstrated that the concentration
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needs to be 100x greater than physiologic levels to strongly inhibit crystal aggregation.71
Interestingly, the inhibitory ability of citrate is halted when all other macromolecules are
removed from the urine.68 In addition, citrate inhibited urease-induced crystallization and
delayed the onset of nucleation and growth of struvite crystals.84 An indirect mechanism
of improved inhibition may be the increased effectiveness of citrate at higher pH levels.68
The benefits of citrate in calcium oxalate stone disease is well understood, but it’s role in
infectious stone disease is not as clear. In vitro studies suggest there may be untapped
potential with this urinary modulator and infectious stones.

1.7.5

Glycosaminoglycans (GAGs)
GAGs are broadly characterized as linear polysaccharides with amino sugars.

There are several GAGs identified in the urine including heparan sulfate, chondroitin
sulfate (chondroitin A and C), dermatan sulfate, and hyaluronic acid. Normal level of
GAGs in non-stone formers is 0-50 moles per 24 hours.68 GAGs are an important part of
bladder defence by being present in the urothelial lining and preventing bacterial
adhesion. If bacteria cannot adhere to the urothelium and proliferate then this would
prevent infection stones from forming.85 There has not been a consistent demonstration in
the literature that stone formers and non-stone formers have significantly different levels
of GAGs in the urine.68
Chondroitin sulfate (CS) is the most abundant GAG in urine and is present within
struvite and calcium phosphate stones, but not calcium oxalate stones.24 Despite its
presence, chondroitin sulfate appears to have no effect on calcium phosphate crystal
formation.86 There may be some inhibitory effect by heparin with calcium oxalate
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crystallization, but heparin has no impact on urease-induced stone crystallization.80,82 In
vitro studies by Torzewska and Rozalski showed that chondroitin sulfate in Griffith’s
artificial urine infected with Proteus mirabilis actually led to increased struvite and
apatite crystallization.83
Hyaluronic acid (HA) is an extremely large and high molecular weight GAG. Its
size, negative ionic charge, and ability to form hydrated gel-like matrices make it an
excellent binding molecule for stone formation. High fluid intake leads to high interstitial
HA in the kidney which prevents calcium phosphate precipitation by binding Ca2+ with
the COO – in the HA matrix. This is important because of the role of Randall’s plaque
formation (calcium phosphate deposits) and kidney stone development.24 The exact type
of GAGs that are clinically impactful is not entirely clear. It is possible that GAGs could
be promoters or inhibitors and the difference could depend on stone type, molecular
structure, or both.

1.7.6

Tamm-Horsfall Protein (THP)
THP, also known as uromodulin, is one of the most abundant proteins in normal

human urine and is a major component of urinary casts. There is a large variation in daily
excretion of THP in urine ranging from 20-100 mg/day.24 While being one of the more
extensively investigated urinary modulators in the literature, the results of these studies
have not been consistent. The amount of THP excreted between healthy subjects and
stone formers is not significantly different, but there is less carbohydrate (sialic acid)
present in THP excreted in from stone formers.79 Some have posited that THP may have
a moderate inhibitory effect on calcium oxalate and calcium phosphate
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crystallization.86–88

1.7.7

Nephrocalcin
Nephrocalcin was first identified in 1978 by Nakagawa et al.24 and is composed of

110 amino acid residues where 25% of which are glutamic and aspartic acid. There are
also 2 cysteine and 2-3 -carboxyglutamic acid (Gla) molecules attached.68 It has been
localized in the proximal tubules and thick ascending loops of Henle in the kidney and
the daily excretion is 5-16 mg/day.68 Coe et al. demonstrated how nephrocalcin could
inhibit calcium oxalate formation by 50%.88 Initially, it was thought to be a potent
inhibitor of calcium oxalate, but further investigation estimates a more limited role of
about 16% of total crystallization inhibition in the urine.68

1.7.8

Osteopontin (OPN)
OPN is a negatively-charged aspartic acid rich protein79 and is found in multiple

locations throughout the body including the kidneys, gastrointestinal tract, gallbladder,
pancreas, lung, salivary gland, inner ear and bone. It is involved in several biological
functions including leukocyte recruitment, cell survival, inflammation, wound healing,
and mineral modulation. It has also been called uropontin, but nucleotide sequencing
showed that uropontin was not a distinct protein and just a urinary form of OPN.24 OPN
is found in the thick ascending limb of the loop of Henle and distal convoluted tubules
within the kidney and its expression is upregulated by phosphate and pyrophosphate.
Normal urinary concentration of OPN is around 100nM and the expression of
OPN increases with injury and the inflammatory process associated with healing.68,79
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OPN is detected in the calcium phosphorus deposits of Npt2a-/- mice and is thought to
affect intraluminal and interstitial renal mineralization.89 Urine OPN levels is inversely
correlated with percent of calcified area in kidney sections obtained from the mice
Npt2a-/-.89 OPN has also been identified in calcium oxalate monohydrate, calcium oxalate
dihydrate and uric acid stones. In addition, there have been studies showing in vivo and in
vitro inhibition of calcium oxalate stone formation and decreased aggregation of calcium
phosphate crystal formation with OPN.68,86

1.7.9

Inter--Inhibitor (II)
II and other related molecules fall under plasma protease inhibitors, which are

typically synthesized in the liver. They are comprised of heavy chains covalently linked
to a light chain called bikunin.68 Urinary excretion ranges from 2-10 mg/day (5.01g/mL
in healthy subjects or 2.54 g/mL in stone patients), but can increase 50-100 times under
certain pathologic conditions such as cancer or decrease in other conditions like renal
failure.24 Isolated bikunin concentrations of 20 µg/mL inhibited crystal nucleation by 9%
and crystal aggregation 21%.24 Bikunin isolated from stone formers shows less sialic acid
compared to bikunin from healthy subjects.68 Furthermore, it appears that bikunin and II
may inhibit calcium oxalate crystallization.

1.7.10 Urinary prothrombin fragment-1 (UPTF-1)
The blood clotting factor prothrombin is degraded into three components and
Fragment-1 is excreted in the urine.79 UPTF-1 has also been called “crystal matrix
protein” and is a principal constituent of calcium oxalate and calcium phosphate stones.24
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Staining has localized UPTF-1 in the cytoplasm in epithelial cells of the thick ascending
limb of the loop of Henle and the macula densa of the kidney.68 The normal daily urinary
excretion is 13.4 nM/day, but can increase to almost 50 nM/day in pregnant women.
UPTF-1 has demonstrated strong inhibition of crystal nucleation, but the effectiveness
can vary depending on an individual’s race.68

1.7.11 Calgranulin/Calprotectin
Calgranulin is a S100 calcium binding protein, and the normal urinary
concentration is 3.5-10 nM. In artificial urine, calprotectin has shown a dramatic effect on
struvite crystal formation by delaying nucleation and decreasing the size of the crystals.90
Calgranulin has been identified in calcium oxalate, calcium phosphate, uric acid, and
struvite stones.24 It has been shown to inhibit calcium oxalate crystal growth and
aggregation at the extremely low concentrations that are observed in human urine.68

1.7.12 Albumin
Albumin is a very abundant urinary protein and has been identified in the matrix
of stones and crystals in human urine. Albumin will bind other urinary proteins and
incorporate them into the stone matrix.24 It appears that albumin can be a promotor or
inhibitor depending on the urinary environment. In vitro urease-induced crystallization
was promoted via albumin by increasing pH and ammonium production, but this effect
did not translate to human urine.91 Albumin has been demonstrated to inhibit calcium
oxalate crystal aggregation, but also to mediate strong crystal nucleation at a pH of 7.0.68
Interestingly, albumin does not appear to have an effect on calcium phosphate
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crystallization.86 While albumin may be an inhibitor in calcium oxalate stone disease, it
could also be neutral or a promoter in infectious stone formation.

1.7.13 Polyaspartic acid (PASP)
PASP is a carboxylated protein that has shown some promise as a urinary
inhibitor. PASP decreases growth kinetics of calcium phosphate at levels of 1 nM and
there does appear to be a dose-dependent response with increasing concentrations leading
to more inhibition.92,93 The inhibitory effect with calcium phosphate crystal formation is
on reducing aggregation.86,94 Structural changes to calcium phosphate crystals in the
presence of PASP has been documented with scanning electron microscopy (SEM).95

1.7.14 Lipids/Cellular membranes
Under normal conditions, there are a small amount of lipids in the urine. Stone
formers tend to have more and different phospholipids in the urine compared to healthy
subjects. Lipids have been demonstrated to be sites of initiation for calcium phosphate
crystals and are found in the matrix of struvite, uric acid, calcium oxalate and calcium
phosphate stones.24,68 Phospholipids appear to promote calcium phosphate and calcium
oxalate crystals while also helping to expand the crystal matrix.24

1.7.15 CD44
CD44 is a extracellular matrix glycoprotein involved in cell-cell interactions that
is a receptor for hyaluronan, HA and OPN.24 CD44 is upregulated during injury and
inflammation and is found on the distal collecting duct cells within the kidney.
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Proliferating cells are open to adhesion by calcium oxalate crystals and it is believed that
an intact epithelium will prevent crystal adhesion so an upregulation of CD44 would be
associated with a higher risk of stone formation.68

1.7.16 Magnesium
Magnesium complexes with oxalate and is more stable than calcium oxalate, this
leads to decreased particle formation by 50%.79 In whole human urine, magnesium
reduces the incidence of calcium oxalate crystal formation that has been subjected to
removal of water in a manner analogous to the collecting tubules of the kidney.96 Oral
magnesium has been shown to decrease oxalate urinary excretion and increase urinary
citrate in hypomagnesemic patients.79 Further evidence suggests that magnesium inhibits
calcium phosphate crystallization, but findings have not been consistent.71,82

1.7.17 Methionine
Methionine has been shown to acidify urine in normal men.97 Oral
supplementation with methionine leads to significant decreases in supersaturation of
brushite and struvite crystals with no effect on calcium oxalate crystallization. Not
surprisingly, the supersaturation increased significantly for uric acid.98 Methionine has
shown success in decreasing infectious stone recurrence in a small cohort of patients and
has also been used to treat an infected and encrusted ureteric stent after a urinary tract
infection.98,99
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1.7.18 Miscellaneous
Vanillic acid added at a concentration of 0.5mg/mL to P. mirabilis infected urine
shows a delay in the pH rise. However, at 2.5-5 mg/mL there was no increase in pH after
24 hours. Vanillic acid at higher concentrations can be bactericidal for P. mirabilis and
can also inhibit urease at very low concentrations.83
Sulfate is predominantly produced by sulfur amino acid oxidation and excreted by
the kidney as a titratable acid. Normal urinary concentration of sulfate is 10 M –
1000M. Sulfate has shown a modest effect in decreasing urinary calcium
supersaturation and raised the upper limit of metastability for calcium oxalate and
calcium phosphate crystal formation.100
Edwards et al. showed that oral phosphate supplementation significantly
decreased urinary calcium and magnesium and increased excretion of citrate. They
demonstrated persistent results with 2 years of follow up with only 2 out of the 20
participants developing stones.101
Zinc has been shown to stimulate calcium aggregation and aid stone formation.71
Curcumin (diferuloylmethane) is a pigment extracted from the roots of turmeric
(Curcuma longa) with effectiveness at reducing urease activity at 1 mM. Curcumin does
not affect struvite crystal morphology, but the crystals are smaller in number and size
compared to a control.102
Urinary modulators in stone formation have been an area of interest in the
scientific community for decades. Despite the extensive exploration, there is limited
clarity of urinary modulators in calcium oxalate stone disease and even less so for
infectious stone disease. Due to the significant urinary biochemical changes with urinary
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tract infections, the effects cannot be assumed to be equivalent. Therefore, testing a wide
variety of these modulators under consistent experimental conditions would be the first
step to further our understanding of infectious stone modulation.

1.8

Experimental models

Recent growth has occurred in the development of animal models for kidney
stone disease, especially with the Drosophila melanogaster model.103–107 Unfortunately,
this model has only been validated for calcium oxalate stone disease and it is unknown
whether or not they can form calcium phosphate or struvite stones. Rat, porcine and
canine are examples of animal models have been used to study stone formation.77,89,108–111
Despite their important use in the pre-clinical study of kidney stone disease, animal
models still have some limitations. For example, only rat and canine models have been
shown to form infectious stones.
Rat models take at least 4 weeks before they are old enough to introduce the
intervention and obtain results.77,89 Nickel et al. were able to circumnavigate this issue by
cultivating bacteria and inoculating the bladder of rats. This was technically challenging
as it required the rat to first be anesthetized and then surgery was performed on it to
introduce the bacteria on a zinc disc through a cystotomy and subsequent closure. Delays
from intervention and results is longer in canines so it has been used less frequently in the
literature. Naito et al. developed a renal cell culture model from canine renal distal
tubular epithelium, which makes the repeatability a bit easier, but it is still a technically
challenging model to use.112
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Other artificial mediums for studying stone development include: gel-based plate
assays, diffusion gels, and polystyrene films that have been used to study biologic crystal
formation.69,113–115 Only the diffusion gel techniques have been used for infectious stone
formation,69 however, a concern with that model is the variability of the experimental
conditions. For example, the pH ranged from 4.5-10 in one test tube, thus making the data
impossible to interpret. Currently, only a basic understanding of infectious stone
pathogenesis exists, and a comprehensive study of a wide variety of urinary modulators
and conditions is needed. This could be accomplished best with a reliable, high yield,
rapid and affordable experimental model that can produce results that could be later used
in animal models or even a clinical study.
High-throughput experimental models have used pooled human urine, non-stone
formers and stone formers urine. While ideal for clinical applicability, it is more difficult
to account for all substances and the various concentrations within human urine that can
affect outcomes. Artificial urine has been used extensively in a plethora of study designs
to stimulate stone formation. Perhaps best known is the work by Griffith et al. who
described a recipe for artificial urine that has been used extensively throughout the
literature.62,70,83,116–118 When required, investigators will alter the chemical composition of
artificial urine to achieve a desired outcome.119 For example, Brooks and Keevil made an
artificial urine that was more directed for the growth of urinary pathogens and not
necessarily the study of stones.120
An area where Griffith’s artificial urine has been used is to investigate struvite
and calcium phosphate stone formation. In an effort to instigate the formation of
infectious crystals, Jack bean urease or inoculation with urease producing bacteria is
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used.62,70,83,84,117–119 The concern with using bacterial inoculation is that the level of
urease could be variable and difficult to control. This is important as the difference in
crystal formation is clearly increased with higher concentrations of urease.70 An increase
in crystal formation is also seen with rising pH so this effect can be limited with a pH
buffer and Tris buffer has been used with good effect.62,70 Ebisuno et al. showed that
Griffith’s artificial urine with Jack bean urease can yield calcium phosphate and struvite
crystals concurrently in varying amounts.117 They were able to confirm the composition
of the crystals on light microscopy and infrared spectrum analysis. One benefit of this
experimental model is that it can yield results within 24 hours and allows investigators to
trial a multitude of urinary modulators under identical experimental conditions.
Given the gap in the research regarding a high-throughput experimental model
that can yield reliable results, this project will attempt to develop and validate a highthroughput experimental model to test urinary modulators in infectious kidney stone
formation. After validation, the model will be used to test a variety of urinary modulators
and to explore the role of different bacterial strains on stone formation.
We have three main aims for this project. Firstly, we plan to create an
experimental model that can successfully produce calcium phosphate and struvite that is
easily reproducible. Secondly, using our validated experimental model, we will test a
variety of urinary modulators and their effects on infectious stone formation. Thirdly, we
will use our experimental model to explore the relationship between bacteria and kidney
stone formation.
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Chapter 2
2

Creating and validating a high-throughput experimental model
for infectious stone formation
Urinary stone disease is an extremely common condition that is recurrent and

increasing in incidence. Infectious stones are more common in vulnerable patients and
can lead to significant morbidity in all those afflicted. It has been well documented that
urease producing bacteria and an elevated urinary pH promote struvite and calcium
phosphate stone formation. However, these stones can also form in the absence of
diagnosed clinical infections which suggests that there are alternative factors mediating
the development of these stones not yet fully appreciated. Understanding the pathways
leading to the formation of these two different stone types may have preventative and
therapeutic implications.
A variety of experimental models have been used to investigate urinary
modulators in infectious stone formation, yet no single model has provided clear and
reliable results to test the long list of possible modulators. The following chapter details
an improved model able to test for these urinary modulators in infectious stone formation.
During our testing stage, multiple urine media, urease concentrations and other
experimental conditions were utilized to try and find an optimal system to compare
different urinary modulators. Model validation occurred by confirming both struvite and
calcium phosphate crystals with the experimental components and conditions used.
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2.1
2.1.1

Introduction

Experimental models
Given the plethora of urinary modulators and bacterial species investigated in

infectious stone formation, a reliable experimental model which allows for consistent
experimental conditions and rapid results is needed. Currently, many models in this
regard have been attempted, however, significant heterogeneity in experimental design
exists which complicates the best approach to study both calcium phosphate and struvite
formation simultaneously.
Diffusion gel growth models have been used to test inhibitors of struvite crystal
formation.1,2 These are made by creating a silica hydrogel with different concentrations of
one reactant (i.e., ammonium dihydrogen phosphate) in a test tube with struvite crystals.
A supernatant of the second reactant (i.e., magnesium acetate) and the modulator of
interest are added to test tubes that are placed under an airtight seal. Downsides to this
technique include the time delay to observe the effects and only one crystal type can be
tested at a time. Diffusion gels take two days to create and potentially weeks to see the
results depending on the experimental end points.1,2 Combining the two reactants in a test
tube has less clinical relevance because it omits other compounds in urine that may alter
the reaction. The use of seed crystals has been used previously to study crystal formation
and growth, however this artificially promotes nucleation to a crystal already formed and
does not naturally allow for neogenesis of struvite and calcium phosphate crystals.3–5
In contrast to the length of time diffusion gel growth models take, microfluidic
devices can monitor calcium phosphate and struvite crystal formation in real-time.6,7 The
purpose of this model is to stimulate renal tubular flow by using a single cell layer within
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a 3D tubular structure and flushing solutions through at a controlled rate. The type of
solution is chosen based on the crystal of interest (calcium oxalate, calcium phosphate,
etc.) during a particular study. Crystals are visible within 20 minutes and their
materialization can be viewed in real-time with microscopy. While the quick results
under stable conditions are desirable, there are limitations to widespread use of this
model. For example, only one crystal at a time can be studied and the specialized
equipment required is very expensive.
The Madine Darby Canine Kidney (MDCK) cell culture model, derived from
canine renal distal tubular epithelium, has been used to study calcium phosphate stone
formation.8 In this case, cells are grown as monolayers in plastic culture flasks, threedimensional soft agar culture or collagen gel culture. Light microscopy is used to count
the colonies with microliths and compare that to the total number of colonies grown over
time. For this technique, it takes weeks for crystal propagation and the maintenance of
cell cultures is quite labour intensive.8
Beyond the three models mentioned above, artificial urine with the addition of
urease has been used to successfully produce calcium phosphate and struvite crystals
simultaneously in the same experiment.9 Benefits of this model setup include consistent
concentrations of the components, relatively low cost, long shelf life of components
involved and the ease at which a large number of urinary modulators can be tested. A
wide range of urease concentrations have been investigated in infectious crystal
formation in prior studies with no evidence to support the most suitable urease
concentration for studying urinary modulators. Monitoring and controlling for pH are
also important considerations in the development of the experimental design as it has
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consistently been shown that increasing pH will accelerate calcium phosphate and
struvite crystal formation.1,10,11

2.1.2

Urine media
In the past, urine from healthy and stone forming humans has been used to study

infectious stone formation.12 Hedelin et al. noted that the crystallization of calcium
phosphate and struvite in urine from individual humans differed markedly.13 In the study,
two patients had the exact same urine pH, but the volume of struvite and calcium
phosphate crystals varied by a factor of 1:5, supporting the premise that other factors are
involved besides urinary alkalinization.13 Furthermore, the composition and components
of human urine also can vary by gender, age, race, weight and diet.14–17
A variety of solutions and artificial urines have been utilized to study stone
formation. In an effort to create a solution to help investigate struvite crystal formation,
Asakura et al. used a “minimal urine solution” comprised of only a few compounds.18
Additionally, modifying calcium concentration has commonly been studied for
differences in the ratio of calcium phosphate and struvite crystal formation.11,18,19
Common types of artificial urine include Griffith’s as well as Brooks and Keevil
(hereto referred to as Brooks). Griffith’s artificial urine was first described in 1976 and
has been frequently used when investigating infectious stone formation.20 Brooks
developed a different artificial urine model to specifically study urinary pathogens, but
they noted formation of rudimentary struvite and calcium phosphate crystals.21
Unsurprisingly, Brooks artificial urine has been used in experimental models for
infectious kidney stone formation.22 Despite these prior studies, the ideal urine media and

54
experimental conditions have not been clearly elucidated for the study of infectious stone
formation.
The purpose of this study was to identify the best urine media and urease
concentration to study infectious stone formation. We hypothesize that Griffith’s artificial
urine would be the best media for the current study because both calcium phosphate and
struvite crystal have consistently formed in vitro. We aim to identify a urease
concentration that allows crystal formation to occur, but slowly enough that we can add
urinary modulators that will have modifiable and detectable differences in the reaction.

2.2

Materials and Methods

Review ethics board approval from Western University was attained for urine for
testing biomaterials (116471).

2.2.1

Infectious stone experimental model

2.2.1.1 Optimization of crystal forming assay
Griffith’s artificial urine (Table 4)20 and Brooks artificial urine (Table 5)21 was
made as previously described. Both artificial urines were filtered through a 0.22 m pore
vacuum filter and stored at 4C. Jack bean urease (Cat# 94280-5G, Sigma-Aldrich,
Oakville, Ontario, Canada) was partitioned into 50 U/mL aliquots and frozen at -20℃ to
avoid freeze-thaw degradation of the enzyme.
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Table 4: Composition of Griffith’s artificial urine.
Compound
CaCl2•2H2O
MgCl2•6H2O
NaCl
Na2SO4
Na3citrate•2H2O
Na2oxalate
KH2PO4
KCl
NH4Cl
Creatinine
Urea
Initial pH = 5.7

Table 5: Composition of Brooks artificial urine.
Compound
Peptone L37
Yeast extract
Lactic acid
Citric acid
Sodium bicarbonate
Urea
Uric acid
Creatinine
CaCl2•2H2O
NaCl
FeSO4•7H2O
MgSO4•7H2O
NaSO4•10H2O
KH2PO4
K2HPO4
NH4Cl
Initial pH = 6.5

Amount (g/L)
0.65
0.65
4.6
2.3
0.65
0.02
2.8
1.6
1.0
1.1
25.0

Amount (g/L)
1
0.005
0.1
0.4
2.1
10
0.07
0.8
0.37
5.2
0.0012
0.49
3.2
0.95
1.2
1.3

Griffith’s artificial urine, Brooks artificial urine, and human pooled (HPU) from
three non-stone forming female donors were tested. In brief, volumes of 10 mL urine and
concentrations of 0.01 U/mL, 0.02 U/mL, 0.05 U/mL, 0.1 U/mL, 0.2 U/mL, and 0.25
U/mL of Jack bean urease were mixed in test tubes. These urease concentrations were
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selected based on the experiments by Hedelin et al.11 From each reaction, 200 L of urine
was pipetted into a 96-well plate (Sarstedt, Nümbrecht, Germany) in technical duplicate.
Plates were incubated at 37C for 8 hours and absorbance was recorded every 10 minutes
at 660 nm. The Biotek Eon Microplate Spectrophotometer (Winooski, Vermont, USA)
and the Gen 5 v2.0 (Winooski, Vermont, USA) software were used for analyzing all 96well plates.
The next experimental run was completed with Brooks artificial urine, Griffith’s
artificial urine, and human urine from a single male non-stone former. In this
experimental run, a urease concentration over 0.2 U/mL was not tested based on the
results of the previous experiment. Since the precipitation of the reactions were observed
within 2 hours with little change beyond 4 hours, plates were incubated at 37C for 4
hours and absorbance was recorded every 5 minutes at 660 nm.
While this will be elaborated on further, it was important to identify early the
appropriate urease concentration and ideal medium which was determined to be Griffith’s
artificial urine owing to its consistent results and similar growth curves to human media.
Given these findings, Griffith’s artificial urine using concentrations of 0 U/mL, 0.05
U/mL, 0.075 U/mL, 0.1 U/mL, 0.125 U/mL, 0.15 U/mL, 0.175 U/mL, 0.2 U/mL Jack
bean urease were tested. Griffith’s artificial urine with a low calcium concentration (0.4
M) was tested with because Ebisuno et al. showed that a higher concentration of calcium
led to more calcium phosphate crystals compared to a low calcium concentration, which
favours struvite crystal formation.19 Both Griffith’s and low calcium Griffith’s artificial
urine were placed in a 96-well plate in technical triplicate. Plates were incubated at 37C
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for 4 hours and absorbance was recorded every 5 minutes at 660 nm. After 4 hours, pH
levels were assessed using pH test strips (VWR Chemicals BDH, Germany).
The pH levels within the experiments were drastically different, so we added a
Tris buffer to the model. A 1 M Tris HCl pH 8.3 solution was prepared by dissolving
12.114 g Tris in deionized water, pH adjusted by NaOH to a final volume of 100 mL.
Since Tris buffer is temperature sensitive, a buffer with a pH of 8.3 at 20C was made
resulting in a final pH of 8.0 at the incubation temperature of 37C. The solution was then
vacuum filtered through a 0.22 m filter for sterilization. In between experiments, the
Tris buffer was stored at 4C.
The experiment was repeated using Griffith’s artificial urine, a low calcium
concentration (0.4 M) Griffith’s urine and human urine from a non-stone former used
with concentrations of 0.075 U/mL and 0.15 U/mL Jack Bean urease with 40 L 1 M Tris
buffer providing a buffering capacity of 4 mM. Comparative experiments were done with
the same concentration of urease without Tris buffer. Plates were incubated at 37C for 4
hours and absorbance was recorded every 5 minutes at 660 nm. After 24 hours, the pH
values were checked for each reaction.

2.2.1.2 Microscopic analysis of crystal formation
Crystals were collected for microscopy to confirm the presence of struvite or
calcium phosphate crystals after 24 hours of incubation in the test tubes filled with 10 mL
urine media and other reactants. Briefly, crystal suspensions were centrifuged at 1620 × g
(3000 rpm) (Eppendorf 5804 R, Mississauga, Ontario, Canada) for 5 minutes at 22C.
The supernatant was decanted and, using a wide bore pipette, the crystal suspension was
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placed on a microscope slide. Slides were examined under a Nikon Eclipse Ts2R
(Melville, New York, USA) microscope at 400x magnification to look for struvite and
calcium phosphate crystals. Multiple images of the crystals were taken with both the
birefringent lens and white light and processed using NIS elements software (Melville,
New York, USA).

2.2.1.3 Scanning electron microscopy and X-ray diffraction
Each solution was filtered through a 0.22 m vacuum filtration system and the
crystals were washed off the filter paper with deionized water. The crystals were left
suspended in water to allow for preparation for scanning electron microscopy (SEM) and
energy dispersive X-ray spectroscopy (EDX). A random sample of each solution was
mounted on silica and examined with SEM (Zeiss/Leo 1540XB FESEM, Oberkochen,
Germany). EDX (Oxford Instruments X Max 50, England, United Kingdom) was
performed to assess the molecular composition of the crystals.

2.2.1.4 Adjusting Tris buffering capacity
The pH values in the initial experiments were not remaining within a physiologic
range that would be amenable to studying urinary modulators in the model.
Consequently, a second Tris buffer was prepared at 7.52 at 37C. After which, an
experimental run using normal Griffith’s and low calcium Griffith’s artificial urine with
0.075 U/mL and 0.1 U/mL Jack bean urease with the newly modified Tris buffer was
conducted.
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2.2.2

Statistical analysis
Statistical analysis was carried out with RStudio version 2022.02.1 (Boston, MA,

USA) using the Growthcurver package version 0.3.1 to analyze crystal growth curves.23
All graphs and figures were created were accomplished using Prism – GraphPad version
9.3.1(San Diego, CA, USA).

2.3

2.3.1

Results

Experimental model

2.3.1.1 Comparing Brooks and Griffith’s artificial urine to human pooled urine
Concentrations of urease had a clear effect on the timing and rapidity of crystal
formation in all urine media. The crystals formed very quickly with little time from the
initiation of the experiment to crystal formation for the higher concentrations of urease.
As seen in Figure 1, a steep curve on the graph correlates with a more rapid reaction
while the area under the curve demonstrates overall crystal volume in the reaction.
Quantitative values were calculated using “growth curver package” and results from the
first experimental run can be found in Table 6.
Slope of the growth curves (r) for crystal formation were different between the
Griffith’s and Brooks artificial urine as demonstrated in Table 3. When observing the
slopes for all three media at 0.1 U/mL, Griffith’s was 0.027, Brooks was 0.130 and HPU
was 0.038. Overall, the slopes are more similar for a given concentration between
Griffith’s and HPU compared to Brooks. Another area of interest is the doubling time
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(t_gen) of the analysis. A much quicker reaction is demonstrated given that Brooks had a
faster doubling time compared to HPU and Griffith’s (Figure 1). However, such robust
reactions leading to early crystal formation would make it challenging to evaluate added
urinary modulators as the urease might overwhelm the modulating effect. A lower
concentration range was tested to see how it would affect the slopes of the graphs.
Timing of the reactions started within two hours and most of the reactions were
completed by four hours. This shortening of the experimental length and interval time
with the spectrophotometer limits extraneous data and improve efficiency of the model.

Table 6: Growth curve output for Griffith’s, Brooks, and human pooled urine at
varying urease concentrations.
Urine Sample
k
n0
r
t_mid t_gen auc_l auc_e sigma
0.25 U/mL Griffith's 0.30 0.00 0.04 136.21 19.32 103.15 101.98 0.02
0.20 U/mL Griffith's 0.35 0.01 0.03 104.94 22.30 131.68 130.30 0.03
0.1 U/mL Griffith's
0.24 0.01 0.03 138.65 26.15 82.45
81.35
0.02
0.05 U/mL Griffith's 0.15 0.00 0.04 174.64 16.44 45.63
45.39
0.01
0.02 U/mL Griffith's 0.00 0.03 0.12 -0.14
5.61
0.30
0.45
0.00
0.01 U/mL Griffith's 0.00 0.02 0.03 -1.08 24.03
0.36
0.42
0.00
0.25 U/mL Brooks
0.43 0.03 0.18 15.47
3.92 199.36 198.62 0.01
0.20 U/mL Brooks
0.42 0.01 0.19 20.92
3.67 191.17 189.80 0.02
0.1 U/mL Brooks
0.40 0.00 0.13 36.56
5.34 176.24 174.98 0.02
0.05 U/mL Brooks
0.31 0.00 0.07 61.53
9.78 128.22 127.50 0.02
0.02 U/mL Brooks
0.23 0.01 0.02 132.67 29.41 80.58
79.45
0.02
0.01 U/mL Brooks
0.23 0.01 0.02 143.27 28.89 77.10
75.95
0.02
0.25 U/mL HPU
0.08 0.00 0.06 56.28 11.37 32.64
32.50
0.00
0.20 U/mL HPU
0.08 0.00 0.06 64.99 12.30 30.90
30.74
0.01
0.1 U/mL HPU
0.08 0.00 0.04 106.25 18.29 28.14
27.88
0.01
0.05 U/mL HPU
0.05 0.00 0.03 183.11 21.63 15.45
15.23
0.00
0.02 U/mL HPU
0.05 0.00 0.03 235.28 21.55 11.12
11.01
0.00
0.01 U/mL HPU
0.05 0.00 0.03 236.47 20.74 10.94
10.88
0.00
0
k = growth capacity, n = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.
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0.0
0:00:00 1:40:00 3:20:00 5:00:00 6:40:00
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Brooks Artificial Urine
Urease Concentration

0.6

0.25 U/mL

OD 660

0.20 U/mL
0.10 U/mL

0.4

0.05 U/mL
0.02 U/mL
0.01 U/mL

0.2

0.0
0:00:00

1:40:00

3:20:00

5:00:00

6:40:00

Time

Human Pooled Urine
0.20

0.25 U/mL
0.20 U/mL

0.15

OD 660

Urease Concentration

0.10 U/mL
0.05 U/mL

0.10

0.02 U/mL
0.01 U/mL

0.05
0.00
0:00:00

1:40:00

3:20:00

5:00:00

6:40:00

Time

Figure 1: Crystal growth curves with Griffith’s, Brooks, and human pooled urine
with varying urease concentrations measured by absorbance at a wavelength of 660
nm.
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2.3.1.2

Comparing Brooks and Griffith’s artificial urine to human urine
from a non-stone former
Brooks artificial urine had extremely rapid crystal formation even at low urease

concentrations which can be seen in Table 7 with high r values and faster doubling times
(t_gen). This is consistent with the curves seen in Figure 2A. Across the various
concentrations of urease, Brooks developed crystals quicker than both human urine and
Griffith’s artificial urine. Griffith’s artificial urine was noted only to develop crystals at
concentrations of 0.1 and 0.085 U/mL, however, this was not consistent with later
experiments (Figure 5). In contrast, human urine produced crystals at all tested
concentrations of urease. Of the developed crystals, the visual quality was superior in
Griffith’s urine compared to Brooks artificial urine (Figures 2 and 3). The crystals in
Brooks were more widely spaced with less cohesion, thus making accurate identification
under light microscopy more uncertain while the crystals in Griffith’s were easier to
identify and categorize into calcium phosphate and struvite.
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A

Brooks Artificial Urine

Urease Concentration

OD 660

0.5

0.1 U/mL

0.4

0.085 U/mL

0.3

0.06 U/mL
0.045 U/mL

0.2

0.03 U/mL

0.1

0.015 U/mL

0.0
0:00:00

0 U/mL
1:00:00

2:00:00

3:00:00

4:00:00

Time
B

C

Figure 2: A) Crystal growth curves of Brooks artificial urine measured by
absorbance at a wavelength of 660 nm. B) Brightfield microscopy of crystals in
Brooks artificial urine at 400x. C) Polarized microscopy of crystals in Brooks
artificial urine at 400x.
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A

Griffith’s Artificial Urine

OD 660

0.5

Urease Concentration
0.1 U/mL

0.4

0.085 U/mL

0.3

0.06 U/mL
0.045 U/mL

0.2

0.03 U/mL

0.1

0.015 U/mL

0.0
0:00:00

0 U/mL
1:00:00

2:00:00

3:00:00

4:00:00

Time
B

C

Figure 3: A) Crystal growth curves of Griffith’s artificial urine measured by
absorbance at a wavelength of 660 nm. B) Brightfield microscopy of crystals in
Griffith’s artificial urine at 400x. C) Polarized microscopy of crystals in Griffith’s
artificial urine at 400x.
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A

Human Urine

Urease Concentration

0.3

0.1 U/mL

OD 660

0.085 U/mL
0.2

0.06 U/mL
0.045 U/mL
0.03 U/mL

0.1

0.015 U/mL
0 U/mL
0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00

Time
B

C

Figure 4: A) Crystal growth curves of human urine from a non-stone former
measured by absorbance at a wavelength of 660 nm. B) Brightfield microscopy of
crystals in human urine at 400x. C) Polarized microscopy of crystals in human urine
at 400x.
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Table 7: Growth curve output for Griffith’s, Brooks, and human urine from a nonstone former at varying urease concentrations.
Urine Sample
k
n0
r
t_mid t_gen auc_l auc_e sigma
0.1 U/mL Griffith's
0.65
0.01 0.04 103.66 15.81 88.40 90.06 0.04
0.085 U/mL
0.35
0.00 0.08 73.98 9.22 58.60 58.02 0.02
Griffith's
0.060 U/mL
0.41
0.00 0.10 268.00 6.95 0.24
0.38
0.01
Griffith's
0.045 U/mL
0.00
0.04 0.09 -0.30
8.10 0.28
0.35
0.00
Griffith's
0.03 U/mL Griffith's
0.00
0.04 2.97 -0.01
0.23 0.14
0.21
0.00
0.015 U/mL
0.00
0.04 0.61 -0.02
1.14 0.12
0.21
0.00
Griffith's
0 U/mL Griffith's
1907.18 0.00 0.09 375.53 8.18 0.23
0.42
0.00
0.1 U/mL Brooks
0.26
0.02 0.11 25.94 6.51 55.18 55.01 0.01
0.085 U/mL Brooks
0.21
0.01 0.11 25.44 6.50 45.57 45.34 0.01
0.060 U/mL Brooks
0.25
0.00 0.09 45.74 7.87 48.81 48.55 0.01
0.045 U/mL Brooks
0.24
0.00 0.09 49.28 7.78 45.63 45.38 0.02
0.03 U/mL Brooks
0.20
0.00 0.08 72.68 9.13 32.83 32.62 0.01
0.015 U/mL Brooks
0.14
0.00 0.07 125.85 9.46 16.39 16.29 0.01
0 U/mL Brooks
0.00
0.00 0.00 0.00
0.00 0.00
0.00
0.00
0.1 U/mL Human
0.16
0.00 0.10 52.31 7.30 29.95 29.82 0.01
Urine
0.085 U/mL Human
0.15
0.00 0.08 69.15 9.00 25.07 24.94 0.01
Urine
0.060 U/mL Human
0.14
0.00 0.07 78.98 9.32 22.52 22.41 0.01
Urine
0.045 U/mL Human
0.12
0.00 0.06 105.68 11.11 16.53 16.42 0.01
Urine
0.03 U/mL Human
0.11
0.00 0.06 130.11 11.50 11.71 11.66 0.01
Urine
0.015 U/mL Human
0.07
0.00 0.07 201.78 10.10 2.63
2.68
0.01
Urine
0 U/mL Human
0.00
0.00 0.11 -7.18
6.56 0.13
0.13
0.00
Urine
k = growth capacity, n0 = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.
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2.3.2

Determining the effect of urease and calcium concentration on crystal
formation and pH

2.3.2.1 Identifying the optimal urease concentration
Considering the previous experiments, it appeared that any urease concentration
above 0.2 U/mL drove the reaction very quickly, therefore, concentrations of 0.25 U/mL
were removed from further experiments. The pH values from an experimental run
without a pH buffer are demonstrated in Table 8. As can be seen in the table, the pH
values rose with increasing urease concentration as one might expect. A pH over 9 was
likely driving the reaction and would be difficult for urinary modulators at normal
concentrations in human urine to cause an effect. Ideally, a pH of 7.5 would allow for
struvite and calcium phosphate crystals to form without overpowering the potential
effects of a urinary modulator. At this point, no clear and consistent urease concentration
best suited for the model was determined, so further testing was required.

Table 8: pH levels in Griffith’s artificial urine and urease without a buffer after 4
hours.
Urease Concentration
pH
0 U/mL
5.7
0.075 U/mL
7.25
0.1 U/mL
7.50
0.125 U/mL
8.50
0.15 U/mL
8.60
0.175 U/mL
8.80
0.2 U/mL
9.10
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Urease Concentration

0.8

0.2 U/ml
0.175 U/ml

OD 660

0.6

0.15 U/ml
0.125 U/ml

0.4

0.1 U/ml
0.2

0.075 U/ml
0 U/ml

0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00

Time
Figure 5: Crystal growth curves of Griffith’s artificial urine measured by
absorbance at a wavelength of 660 nm.

2.3.2.2 A trial of normal Griffith’s artificial urine compared to low calcium
Griffith’s artificial urine
Normal Griffith’s artificial urine compared to low calcium Griffith’s artificial
urine was trialled to see if it would affect the predominant crystal formed in the
experiment (which has been previously demonstrated19). As the presence of calcium
phosphate and struvite crystals in the experiment were being confirmed, a Tris buffer was
added to help modulate pH. Table 9 shows the pH results after including the Tris buffer
with a set point pH of 8.0. However, despite the buffer, the pH levels still rose close to
9.0. Although the pH was a bit higher than desired, the attempt was to confirm that the
presence of a buffer would still allow for calcium phosphate and struvite crystal growth.
Figures 6 and 7 demonstrate the curves for the 0.15 U/mL urease reactions with and
without a Tris buffer.
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Interpreting EDX starts with observations of the elements with the largest and
highest peaks, representing what the proportion of the structure being analyzed is
comprised of. Silica (Si) is used as a mounting substance so it should be ignored when
analyzing the composition of the molecules. In Figure 6B and 6C, a glass shard crystal
shape is visible which is typical for calcium phosphate. This was also confirmed on
SEM/EDX (Figure 6D and 6E). EDX shows that the structure is predominantly made out
oxygen (O), calcium (Ca) and phosphate (P) elements. Figure 7B and 7C shows the
classic “coffin lid” crystal shape for struvite, which was confirmed on SEM/EDX (Figure
7D and 7E). The struvite crystals show x-ray diffraction largely made up of oxygen (O),
magnesium (Mg) and phosphate (P).
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A

B

0.8
0.15 U/mL Griffith's

OD 660

0.6

0.15 U/mL Griffith's + Tris

0.4

C

0.2
0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00

Time

D

E

Figure 6: A) Crystal growth curves of Griffith’s artificial urine with 0.15U/ml
urease with or without Tris buffer measured by absorbance at a wavelength of 660
nm. B) Brightfield microscopy of calcium phosphate crystals at 400x. C) Polarized
microscopy of calcium phosphate crystals at 400x. D) Scanning electron micrograph
of calcium phosphate crystals with corresponding x-ray diffraction in E.
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A

B
0.4

0.15 U/mL Low Ca Griffith's
0.15 U/mL Low
Ca Griffith's + Tris

OD 660

0.3
0.2

C

0.1
0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00
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Figure 7: A) Crystal growth curves of low calcium Griffith’s artificial urine with
0.15U/ml urease with or without Tris buffer measured by absorbance at a
wavelength of 660 nm. B) Brightfield microscopy of struvite crystals at 400x. C)
Polarized microscopy of struvite crystals at 400x. D) Scanning electron micrograph
of struvite crystals with corresponding x-ray diffraction in E.

Table 9: Urine media and urease with Tris buffer (pH =8.0 at 37C).
Urine Media
Urease Concentration
Griffith’s
0 U/mL
0.075 U/mL
0.15 U/mL

pH
6.0
8.8
8.8

Low Ca Griffith’s

0 U/mL
0.075 U/mL
0.15 U/mL

6.0
8.6
8.8

Human Urine

0 U/mL
0.075 U/mL
0.15 U/mL

6.0
8.8
8.8
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Despite the buffer added to the reaction, pH levels were still reaching 8-9 after 24
hours, which does not reflect most clinical scenarios. Lowering the pH buffering point led
to a more clinically relevant pH levels (Table 10) with gradual crystal time with an
adequate lag time to the start of the reaction (Figure 8). Allowing the full reaction to
occur over a 24-hour period yielded more crystals that were organized with the typical
crystal shapes indicative of calcium phosphate and struvite crystal compositions.

Table 10: Griffith’s artificial urine with a Tris buffer (pH = 7.5 at 37C).
Urease concentration
pH after 24 hours
0 U/mL
6.25
0.075 U/mL
7.25
0.1 U/mL
7.50

Urease Concentration

0.3

0.1 U/mL

OD 660

0.075 U/mL
0.2

0 U/mL

0.1

0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00

Time
Figure 8: Crystal growth curves of Griffith’s artificial urine with a Tris buffer (pH
= 7.5 at 37C) measured by absorbance at a wavelength of 660 nm.
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2.4

Discussion

The results of this study demonstrate that calcium phosphate and struvite crystal
formation can be cultivated in an experimental model with artificial urine. Griffith’s
artificial urine was determined to be the best media to use in the model. The presence of
both calcium phosphate and struvite crystal formation was confirmed using SEM/EDX.
The optimal concentration was 0.1 U/mL of urease to test urinary modulators and the pH
could be controlled using a Tris buffer to limit its effects on crystal formation without
impacting the underlying reaction. Consistent results were yielded within four hours
under the experimental conditions suitable for testing urinary modulators. This model has
broad applicability because it consists of easily accessible compounds found in most labs,
is inexpensive ($0.08 per reaction with urease) and is easily reproducible, as the
individual components can be maintained for a long time under adequate storage
conditions.
While Brooks and Griffith’s artificial urine have both been used in the study of
infectious kidney stone formation, it is clear they produce different results. With Brooks
urine, crystal formation occurred extremely quickly and at very low concentrations of
urease. Brooks was originally developed for assessment of bacterial growth so it is
understandable that it would also promote infectious kidney stone formation.21 The most
obvious difference is the starting pH of Brooks is 6.5, which is higher compared to
Griffith’s artificial urine at 5.7.20,21 This is likely a significant difference because the
urease increases the pH and has a much shorter path to reaching a pH of 7.0 when struvite
stones crystals would start to form.11 Furthermore, it is also possible that calcium
phosphate crystals would start forming prior to this pH level, but higher pH favours
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calcium phosphate crystal formation.24 Although the pH of Brooks was not measured, it
would be interesting to see if the pHs were typically higher in Brooks for the same urease
concentration compared to Griffith’s. Brooks pH could have been lowered to match
Griffith’s, but it was important to follow the recipes as described with no modifications.
The overall goal of this work was not to create a new artificial urine, but to identify of the
ones already established which would serve as the best media.
Not only was the starting pH different, but the compounds and concentrations
differed as well between the artificial urine media. Brooks artificial urine does not have
any oxalate, which may promote calcium phosphate stones rather than calcium oxalate
crystals compared to Griffith’s artificial urine. Calcium oxalate formation is not
dependent on pH so this reaction could occur prior to calcium phosphate or struvite
formation, but this is impossible in Brooks artificial urine.25 There is also less citrate in
Brooks artificial urine, which is a risk factor for calcium phosphate crystallization.26
Clinically this would correlate with a patient with hypocitraturia or distal renal tubular
acidosis which is not an appropriate baseline in vitro scenario and limits its broad
applicability.
When comparing Griffith’s artificial urine to human urine crystal formation,
notable differences were observed. The slopes of the curves were not as steep in human
urine and the peak of the curves were typically lower than Griffith’s. This is an important
distinction as it is direct evidence that there are natural modulating factors within human
urine that are not possible to replicate in this scenario. Likely this is due to additional
proteins or compounds not found in Griffith’s that can be found in human urine.
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Identifying these modulators may allow their targeted manipulation to effect clinical
stone formation, which is something we hope to later achieve with our model.
A benefit of the model is that results can be seen within 2-3 hours and numerous
inhibitors can be tested at once. Analyzing the reaction with spectrophotometry for 4
hours elicited adequate growth curve analysis, but more definitive results occurred when
carrying out microscopic evaluation after 24 hours. Allowing the reaction to occur over
24 hours improved crystal morphology viewed under the microscope and with more
crystal yield.
As mentioned earlier, concentrations of urease in prior experiments have varied
widely in the literature.11,19 A urease concentration of 0.1 U/mL provides the appropriate
experimental conditions to study urinary modulators, but it is currently unknown how this
might compare to urease concentrations typically found in the presence of urease
producing bacteria. It is possible that the concentration varies based on bacterial strain, an
active urinary tract infection or the amount of colony forming units.27–29 In an effort to
make the reaction more clinically applicable, this would be a logical area to investigate
further.
Throughout this experiment, only urease concentrations of 0.1 U/mL formed
crystals in Griffith’s artificial urine (Figure 3), however, this was not seen in later
experiments (Figure 5) and could be due to degradation of the urease enzyme. More than
one vial of urease is required for each experiment; therefore, it is possible that some of
the reactions could occur normally while select individual experiments did not have
effective urease. Repeating experiments with lower urease concentrations below 0.085
U/mL showed that Griffith’s artificial urine would produce crystals (Appendix B).
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As seen throughout this chapter, decreasing the concentration of calcium in the
artificial urine drove the reaction toward the formation of struvite crystals. In their study
on urease-induced crystallization in human and synthetic urine, Ebisuno et al. not only
reduced, but eliminated calcium completely from the reaction and were therefore able to
yield solely struvite crystals.19 While not clinically applicable in human urine, it can be a
consideration if looking to isolate struvite over calcium phosphate and to investigate
modulators or other properties specific to their formation.
For regular Griffith’s artificial urine, there is an earlier take off for the reaction,
steeper slope, and higher peak than low calcium Griffith’s artificial urine. This was seen
in both reactions with and without a Tris buffer when comparing it to the low calcium
Griffith’s. It is possible that this could be due to the earlier calcium phosphate
crystallization as it can form in more acidic conditions, thus beginning before the struvite
crystal formation. This premise of early and late phase crystallization has been previously
demonstrated in a study by Ebisuno et al. (1997) when separating calcium phosphate
(early phase) and struvite (late phase) crystallization.19
Our results show that there is a difference when using a pH buffer with urease in
urine. While the speed of the reaction may not differ significantly, the peak of the curve
is much lower. We demonstrated that a Tris buffer in the reaction does not prevent the
formation of calcium phosphate and struvite crystal formation. In fact, we determined
that it is critical to minimize the effect of pH as a confounding variable when testing
urinary modulators in infectious stone formation because of the rapid and increased
crystal growth seen with higher pHs.
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Infectious kidney stones are highly recurrent with the risk of recurrence as high
as 75% within 5 years.29 Struvite stones can commonly lead to staghorn calculi that can
form within 4-6 weeks. 30 Patients at risk include those with spinal cord injuries, chronic
indwelling catheters, neurogenic bladders, ileal conduits or ureteral reflux.31–33 There is
limited success with medical therapies to decrease the risk of recurrent infection-based
stones. Antibiotics have limited ability to infiltrate the stone matrices and there are
obviously concerns with long term antibiotic use that can lead to secondary infections and
bacterial resistance.34
Infection-related stones typically require more invasive surgical management with
more technical challenges given the stone characteristics. Calcium phosphate stones are
typically hard stones that are resistant to SWL, also impacting their surgical
management.35 Treating these endoscopically or percutaneously takes more time because
they can be more dense (calcium phosphate) and much larger (struvite and/or calcium
phosphate). If larger staghorn calculi are not managed in a timely fashion it can lead to
renal loss, sepsis or death.36
Taking the model through this rigorous process of trialling multiple variables to
yield the best results has created a validated model that is well-suited for testing urinary
modulators. Using a consistent urease concentration of 0.1 U/mL with a Tris buffer with
a set point of 7.5 allows for rapid, high throughput testing of many urinary modulators to
assess their effect on infectious crystal formation. The benefits of this model provide us
with the opportunity to identify new or add more supportive evidence for urinary
modulators in infectious stone formation. The clinical importance of such a significant
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discovery cannot be understated and the following chapter will outline our breakthroughs
and how they might shape clinical practice.
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Chapter 3
3

Testing urinary modulators in infectious stone formation using
a high-throughput experimental model
Scientific interest into the pathogenesis of kidney stones has been ongoing for

centuries, however, most of this research has focused on one stone type, calcium oxalate.
There is a paucity of knowledge on the pathogenesis of infectious kidney stones including
urinary modulators that may promote or inhibit their formation. In the previous chapter, it
was shown that human pooled urine had a less robust reaction with urease compared to
artificial urine media. This suggests that there may be natural modulators within human
urine that we have not fully elucidated. Now that we have developed and validated a
high-throughput experimental model, we have a unique opportunity to explore the
profound knowledge gap in the pathogenesis of infectious stones from a basic science and
clinical perspective.
An experimental model using Griffith’s artificial urine, Jack bean urease and a
Tris buffer can provide a rapid experimental model with strict conditions to test infectious
stone modulators. The urinary modulators selected for this study were prioritized based
on the quality of evidence in the literature. Additional compounds were included based
on anecdotal evidence in our lab for demonstrating calcium oxalate stone modulation.
Growth curve analysis, pH changes and crystal structure with light microscopy were used
to evaluate the results from the experiments. The comparison of these data points will
allow us to better understand the pathogenesis of infectious stones and propose
therapeutic approaches to minimize risk of infectious stone formation in patients.
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3.1
3.1.1

Introduction

Infectious stone pathogenesis
Currently, the general consensus is to associate infectious stones with UTIs and

the bacteria that cause them, rather than an underlying metabolic abnormality in these
cases. The basis of infectious stones forming in association with UTIs is the result of
urease-producing bacteria converting urea into ammonium and carbon dioxide. The
ammonium leads to a rise in pH and provides more favourable crystal formation for
calcium phosphate and struvite stones.1,2 However, calcium phosphate stones are known
to form in the absence of UTIs with hypercalciuria (i.e., primary hyperparathyroidism)
and hypocitraturia (i.e., dRTA). There are two hypotheses for calcium phosphate stone
formation without any clinical signs of a UTI. Firstly, a clinically asymptomatic UTI was
responsible for the stone formation and secondly, an infectious process was involved in
the initial steps of the stone formation and disappeared secondarily.3
On the other hand, struvite stone formation is almost always associated with UTIs
and is not known to form without the presence of urease-producing bacteria. Although
struvite stones require an alkaline pH, they have been shown to be more resilient to pH
changes compared with calcium phosphate crystallization.4 Maximal crystallization for
both calcium phosphate and struvite occurs between pH of 7.5-8.0.2 The importance of
pH for both calcium phosphate and struvite crystal formation is well documented and it
will be a significant variable in our model. A high pH in the reaction could mitigate or
alter the effect of the modulator and the goal is to minimize potential confounders to
optimize the conditions for the potential modulators being investigated.
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3.1.2

Urinary modulators
There is a long list of compounds associated with non-infectious kidney stone

modulation,5 but an active infection radically alters the urinary environment and can alter
the function of these urinary modulators. For example, inhibitors for calcium oxalate
stone disease could act as promoters of infectious stone formation because of the elevated
pH, presence of bacteria, or other biochemical factors that are present in the infectious
urinary environment. The following paragraphs will provide a brief summary of the
existing literature on the modulators selected for this project.
In vivo data suggests that pyrophosphate acts as an inhibitor of crystal nucleation.6
Sodium pyrophosphate, specifically, has no influence on pH changes, urease activity and
bacterial growth.7 Ethane-1-hydroxy-1,1-diphosphonate (EHDP or etidronic acid)
displaces previously bound pyrophosphate on calcium phosphate crystals and has been
shown to be a more effective inhibitor of calcium phosphate crystals compared to
pyrophosphate.7 Citrate demonstrates urease-induced crystal inhibition and it delayed
onset of nucleation and growth of struvite crystals.8 Chondroitin sulfate (CS) appears to
have no effect on calcium phosphate crystal formation,9 but in vitro studies with Proteus
mirabilis in Griffith’s artificial urine actually led to increased struvite and calcium
phosphate crystallization.7 There may be some inhibitory effect by heparin with calcium
oxalate crystallization, but heparin has no impact on urease-induced stone
crystallization.10,11
OPN tested in vivo and in vitro demonstrates decreased aggregation of calcium
phosphate crystal formation.5,9 Structural changes to calcium phosphate crystals in the
presence of PASP has been documented with scanning electron microscopy,12 as well as
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decreased calcium phosphate crystal aggregation.9,13 Evidence suggests that magnesium
ions inhibit calcium phosphate crystallization, but these findings have not been
consistently shown.10,14 Methionine has been shown to acidify urine in normal men15 and
oral supplementation leads to significant decreases in supersaturation of calcium
phosphate and struvite crystals with no effect on calcium oxalate crystallization.16 High
quality clinical data on the effects of methionine is lacking.
Vanillic acid can inhibit urease enzymes at very low concentrations and at higher
concentrations it can be bactericidal for P. mirabilis.7 Sulfate is a titratable acid in the
kidney with a modest effect in decreasing urinary calcium supersaturation and raising the
upper limit of metastability for calcium oxalate and calcium phosphate crystal
formation.17 Zinc ions have been shown to stimulate calcium aggregation and aid stone
formation.14
Given the lack of evidence for these modulators in infectious stone formation, we
set out to test these substances in our model to determine their ability to modulate
infectious crystal formation. The culmination of this research will further assist in
developing a rudimentary understanding of the pathogenesis of infectious stone formation
and determine substances that could be used to significantly reduce the clinical burden.

3.2

Materials and Methods

As this was an in vitro study, IRB approval from Western University was not
required.
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3.2.1

Experimental conditions for model
The base components for the model included Griffith’s artificial urine, 0.1 U/mL

Jack Bean urease and 1M Tris buffer (pH = 7.52 at 37℃). Once we had selected our
urinary modulators, we next determined the appropriate concentration for each (Table
11). For those compounds found in human urine, the normal human urinary
concentrations were used in the assay. If there is a range of concentrations for a particular
compound, then a value was selected from the upper half of the range. These
concentrations were then multiplied by a factor of 10 to amplify any modulatory effect.
For those compounds that are not normally found in human urine, concentrations were
selected if they were previously used in the literature, or a concentration of 1 mM was
used if there was no prior relevant data.

3.2.2 Making stock solutions for each urinary inhibitor
Stock solutions of each inhibitor were made with 100 mL of Griffith’s artificial
urine and 1 mL 1 M Tris buffer (pH buffering = 7.52 at 37℃) at the corresponding
concentrations in Table 11. The concentration of Tris buffer results in a buffering
capacity of 10 mM for each experiment. After creating the stock solutions, the initial pH
was taken using a Mettler-Toledo FiveEasy Plus pH meter F20 (Gerifensee, Switzerland).
The solutions were then filter sterilized through a 0.22 m filter and stored at 4℃.

Table 11: Concentrations of urinary modulators.5,18–23
Modulator
Concentration
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Heparin
Osteopontin (OPN)
Sodium pyrophosphate
Vanillic acid
Zinc sulfate
Etidronic acid
Polyaspartic acid (PASP)
Chondroitin sulfate
Methionine
Citric acid
Sodium citrate
Magdolate (magnesium pidolate)
Aspartic acid
Indole
Metformin
Sodium bicarbonate
Salicylic acid
P-cresol
Ibuprofen

3.2.3

5 M
600 nM
250 M
375 M
3.1 M
25 M
10 M
47 M
300 M
1.6 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM
1 mM

Running experimental model with urinary modulators
Ten mL of the stock solution was placed into a test tube and mixed with 0.1 U/mL

urease. Control reactions included Griffith’s artificial urine with 0.1 U/mL urease and 10
mM Tris buffer or Griffith’s artificial urine with 10 mM Tris buffer only. A volume of
200 L was pipetted into the 96-well plate in technical triplicate for each reaction. The
Biotek Eon Microplate Spectrophotometer (Winooski, Vermont, USA) and the Gen 5
v2.0 (Winooski, Vermont, USA) software were used for analyzing all 96-well plates. The
reader was set at an optical density of 660 nm at 37C with readings every 5 minutes for
24 hours. The remaining solutions were placed in an incubator at 37C for 24 hours.
After 24 hours, the test tubes were measured for pH levels using the Mettler-Toledo
FiveEasy Plus pH meter F20 (Gerifensee, Switzerland). A 3-point calibration of the pH
meter was performed prior to taking the pH measurements. The test tubes were then

88
visually interrogated for crystal growth, and this was compared with the crystal growth
curves. If there was no evidence of crystal growth, then no further testing was performed
for those particular modulators.

3.2.4

Microscopic analysis of crystal formation
To evaluate the presence of struvite or calcium phosphate crystals, we collected

the crystals from the test tubes for microscopic analysis after 24 hours. During our model
validation (see Chapter 2), it was determined that centrifuging the crystals made
microscopic analysis more challenging because of the significant volume of crystals
transferred to the slide. Therefore, this aspect was omitted from this part of the project.
The supernatant was decanted and 10 μL of the crystal suspension was placed on a
microscope slide using a wide bore pipette. Slides were examined under a Nikon Eclipse
Ts2R (Melville, New York, USA) microscope and multiple images of the crystals were
taken in both the birefringent lens and white light and processed using NIS elements
software (Melville, New York, USA).

3.2.5

Statistical analysis
Statistical analysis was carried out with RStudio version 2022.02.1 (Boston, MA,

USA) using the Growthcurver package version 0.3.1 to analyze crystal growth curves.24
All graphs and figures were created were accomplished using Prism – GraphPad version
9.3.1(San Diego, CA, USA).

3.3

Results
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3.3.1

Urinary modulators that prevented crystal formation
The list of urinary modulators that were not associated with crystals formation in

the reaction include: etidronic acid, ibuprofen, metformin, salicylic acid, citric acid, zinc
sulfate (Zn sulfate), aspartic acid, magdolate and sodium citrate (Na citrate). Table 12
demonstrates the pH levels before and after the experiment regarding these modulators.
The initial pH values for all these modulators were lower than Griffith’s with Tris buffer
(pH = 5.70). After completing the experiments most of the pHs values increased, but the
highest pH was with Na citrate in biologic replicate number 3 at 6.42. In biologic
replicates number 1 and number 2, none of the urinary modulators had a pH above 6.0.

Table 12: pH values of urinary modulators with no crystal growth before and after
experiment.
Modulator
Initial pH
Biologic rep #1 Biologic rep #2 Biologic rep #3
Etidronic acid
1.39
1.09
1.11
1.11
Ibuprofen
4.76
4.81
5.74
6.23
Metformin
5.01
4.92
5.82
6.20
Salicylic acid
4.89
4.84
5.76
6.05
Citric acid
2.93
2.81
3.82
3.90
Zinc sulfate
4.99
5.01
5.91
6.13
Aspartic acid
5.01
4.92
5.86
6.37
Na citrate
4.85
5.07
5.86
6.42
Magdolate
4.96
4.99
5.80
6.21
Griffith’s with
5.02
7.69
8.17
8.72
urease and Tris
Griffith’s with
5.01
5.00
5.87
6.23
Tris

Growth curves for all these reactions were essentially horizontal and at least one
biologic replicate showed all zeroes with growth curve analysis, however, some did
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produce values. Further inspection of these values showed a very low r (growth rate) and
very little AUC demonstrating very minimal growth over time. No crystals were seen
visually in the test tubes with these modulators over the course of any of the experiments.

Table 13: Growth curve output for urinary modulators with no crystal formation.
k

n0

r

Etidronic acid

0

0

0

0

0

0

0

0

Ibuprofen

0

0

0

0

0

0

0

0

Metformin

0

0

0

0

0

0

0

0

Salicylic acid

0

0

0

0

0

0

0

0

Citric acid

0

0

0

0

0

0

0

0

Zinc sulfate

0

0

0

0

0

0

0

0

Aspartic acid

0

0

0

0

0

0

0

0

Na citrate

0

0

0

0

0

0

0

0

Magdolate

0

0

0

0

0

0

0

0

Modulator

t_mid t_gen

auc_l auc_e sigma

k = growth capacity, n0 = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.

3.3.2

Urinary modulators that inhibited crystal formation
The only inhibitor that demonstrated strong inhibition while allowing crystal

formation is OPN. The pH values show that the initial pH was higher compared to our
control and resulting pH values after the experiment for all 3 biologic replicates were
higher compared to Griffith’s with urease and Tris (pH ~ 8.17). Figure 1A shows a
spectrophotometry growth curve for OPN and this was plotted out to 24 hours to fully
appreciate the difference in curves compared to the controls. OPN has an r = 0.008 and
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t_mid = 447.93, which is approximately double compared to Griffith’s with urease and
Tris with a much lower area under the curve (AUC). Interestingly, the crystals were
consistent with struvite on light microscopy (Figure 9B and 9C) with no obvious calcium
phosphate crystals found.

Table 14: pH values of osteopontin before and after experiment.
Modulator
Initial pH
Biologic rep #1 Biologic rep #2 Biologic rep #3
OPN
6.15
9.19
9.28
9.23
Griffith’s with
urease and
5.02
7.69
8.17
8.72
Tris
Griffith’s with
5.01
5.00
5.87
6.23
Tris

Table 15: Growth curve output for osteopontin.
Modulator
OPN
Griffith’s with
urease and Tris

k

n0

r

t_mid

t_gen

auc_l

auc_e

sigma

0.119 0.003 0.008 447.93 85.29 117.64 118.15

0.008

0.270 0.030 0.010 224.58 69.64 320.56 318.52

0.020

Griffith’s with Tris 0.000 0.000 0.000
0
0
0
0
0.000
0
k = growth capacity, n = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.
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A

OPN

OD 660

0.5
0.4

OPN

0.3

Griffith's with urease and Tris
Griffith's with Tris

0.2
0.1
0.0
0:00:00

6:00:00

12:00:00 18:00:00 24:00:00

Time

B

C

Figure 9: A) Crystal growth curve of OPN measured by absorbance at a
wavelength of 660 nm. Bright field microscopy (B) and polarized light
microscopy (C) of struvite crystal from OPN reaction at 200x.

3.3.3

Urinary modulators that promoted crystal formation
In contrast to the modulators that prevented crystal formation, the following

modulators were found to promote infectious crystal formation: indole, chondroitin
sulfate (CS), sodium bicarbonate (Na bicarbonate) and vanillic acid promoted infectious
crystal formation. The initial pH values were greater for CS, indole, and vanillic acid but
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not Na bicarbonate when compared to the controls. However, after the experiments all pH
values were equivalent or increased compared to controls. In Figure 10, the growth
curves start earlier in time and have a greater AUC, which is consistent with the r and
t_mid (Table 17) values for the modulators except for Na bicarbonate. The only
modulator that had an equivalent r with the control was Na bicarbonate while, the rest
had a greater r and shorter t_mid. AUC values for these modulators were also all greater
compared to the controls with CS having the largest empiric AUC 652.15.
Table 16: pH values of urinary modulators that promote crystal growth before and

after experiment.
Modulator
Na bicarbonate
Indole
CS
Vanillic acid
Griffith’s with
urease and Tris
Griffith’s with
Tris

Initial pH
5.11
6.34
6.18
6.17

Biologic rep #1 Biologic rep #2 Biologic rep #3
7.35
8.49
8.69
8.66
8.77
8.83
8.97
8.97
9.06
8.83
8.90
8.90

5.02

7.69

8.17

8.72

5.01

5.00

5.87

6.23

0.8

Na Bicarbonate
Indole

OD 660

0.6

Chondroitin Sulfate
Vanillic Acid
Griffith's with urease
and Tris

0.4
0.2
0.0
0:00:00

Griffith's with Tris

1:00:00

2:00:00

3:00:00

4:00:00

Time
Figure 10: Crystal growth curves for modulators that promote crystal formation
measured by absorbance at a wavelength of 660 nm.

94
Table 17: Growth curve output for urinary modulators promoting crystal
formation.
k

n0

r

t_mid

t_gen

auc_l

auc_e

sigma

Na
Bicarbonate

0.410

0.060

0.010

215.31

89.28

493.39 491.26

0.030

Vanillic acid

0.302

0.086

0.011

81.22

60.95

401.88 401.16

0.022

Indole

0.317

0.073

0.012

102.91

58.65

417.24 416.18

0.025

Modulator

CS
0.489 0.093 0.016 90.81 43.39 653.59 652.15 0.032
Griffith’s with
urease +Tris
0.270 0.030 0.010 224.58 69.64 320.56 318.52 0.020
Griffith’s with
Tris
0.000 0.000 0.000
0
0
0
0
0.000
k = growth capacity, n0 = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.

Crystals from CS (Figure 11) and Na bicarbonate (Figure 12) are shown below.
Both modulators appear to predominantly have calcium phosphate crystals from the
reaction. On close inspection of Figure 11, one can see that the crystals from CS appear
larger and better defined than the Na bicarbonate crystals. There was no clear evidence of
struvite crystals on microscopic assessment with these modulators.

A

B

Figure 11: Brightfield (A) and polarized (B) microscopy of crystals from
chondroitin sulfate reaction at 100x.
B
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A

Figure 12: Brightfield (A) and polarized (B) microscopy of crystals from Na
bicarbonate reaction at 100x.

3.3.4

Urinary modulators with no effect on crystal formation
The modulators that had a largely neutral effect despite their pH values starting

relatively low were found to be methionine and heparin. After conducting the experiment,
the pH levels, slope of the curves and t_mid were similar to Griffith’s with urease and
Tris. The visual overlap of the curves in Figure 13 demonstrates the comparable reaction
dynamics between methionine, heparin and Griffith’s with urease and Tris.

Table 18: pH values of urinary modulators with no effect on crystal growth before

and after experiment.
Modulator
Initial pH
Methionine
5.00
Heparin
5.01
Griffith’s with
5.02
urease and Tris
Griffith’s with
5.01
Tris

Biologic rep #1 Biologic rep #2 Biologic rep #3
7.19
8.04
8.48
7.64
8.16
8.53
7.69

8.17

8.72

5.00

5.87

6.23
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0.8
Methionine

OD 660

0.6

Heparin
Griffith's with urease
and Tris

0.4

Griffith's with Tris

0.2
0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00

Time
Figure 13: Crystal growth curves for modulators with a no effect on crystal
formation measured by absorbance at a wavelength of 660 nm.

Table 19: Growth curve output for urinary modulators with no effect on crystal
formation.
Modulator
Methionine

k

n0

r

t_mid

t_gen

auc_l

auc_e

sigma

0.430

0.040

0.010

288.04

87.04

487.62 484.21

0.030

Heparin
0.420 0.040 0.010 295.75 87.1 472.85 469.46 0.030
Griffith’s with
urease and Tris 0.270 0.030 0.010 224.58 69.64 320.56 318.52 0.020
Griffith’s with
Tris
0.000 0.000 0.000
0
0
0
0
0.000
0
k = growth capacity, n = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.
3.3.5

Urinary modulators with mixed effect on crystal formation
The modulation and pH changes of sodium pyrophosphate (Na pyrophosphate),

PASP and P-Cresol were mixed. The pH of PASP was consistently higher than the
control, but the other reactions had pHs similar to controls, except for biologic replicate
number 1 for Na pyrophosphate.
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Table 20: pH values of urinary modulators with mixed effect on crystal growth
before and after experiment.
Modulator
Initial pH Biologic rep #1 Biologic rep #2 Biologic rep #3
Na pyrophosphate
5.06
5.07
8.21
8.39
PASP
6.17
8.71
8.75
8.72
P-Cresol
6.18
8.04
8.15
8.09
Griffith’s with
5.02
7.69
8.17
8.72
urease and Tris
Griffith’s with
5.01
5.00
5.87
6.23
Tris
As can be seen in Figure 14, the growth curves all started earlier than Griffith’s
with urease and Tris while the slopes appear more gradual. The r values for PASP and PCresol were lower, but Na pyrophosphate had the same r as the control with urease. Tmid (303.38) and t_gen (113.92) were both lower for Na pyrophosphate over PASP, PCresol and controls. While the t_mid values for PASP and P-Cresol are comparable to
Griffith’s with urease and Tris, but t_gen is slightly higher. Overall, the only modulator
that decreased overall crystal growth is P-Cresol.

Na Pyrophosphate
0.8

P-Cresol
PASP

OD 660

0.6

Griffith's with urease
and Tris

0.4

Griffith's with Tris

0.2
0.0
0:00:00

1:00:00

2:00:00

3:00:00

4:00:00

Time
Figure 14: Crystal growth curves for modulators with mixed effect on crystal
formation measured by absorbance at a wavelength of 660 nm.
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Table 21: Growth curve output for urinary modulators with mixed effect on crystal
formation.
k

n0

r

t_mid

t_gen

auc_l

auc_e

sigma

Na
Pyrophosphate

0.430

0.060

0.010

303.38

113.92

477.46

474.88

0.020

PASP

0.510

0.061

0.009

231.06

80.22

608.66

605.69

0.029

Modulator

0.228
0.032
0.008 225.82 86.64 272.01 270.46 0.017
P-Cresol
Griffith’s with
0.270
0.030
0.010 224.58 69.64 320.56 318.52 0.020
urease +Tris
Griffith’s with
0.000
0.000
0.000
0
0
0
0
0.000
Tris
k = growth capacity, n0 = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.

Crystals formed with Na pyrophosphate, P-Cresol and PASP are shown in the
figures below. Overall, these crystals are smaller compared to CS and Na bicarbonate. Na
pyrophosphate and PASP appear to have calcium phosphate crystals, but P-Cresol
appears to have struvite crystals with the “coffin lid” shape.

A

B

Figure 15: Brightfield (A) and polarized (B) microscopy of crystals from Na
pyrophosphate reaction at 200x.

A

B
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A

B

Figure 16: Brightfield (A) and polarized (B) microscopy of crystals from PCresol reaction at 200x.

B

A

Figure 17: Brightfield (E) and polarized (F) microscopy of crystals from PASP
reaction at 200x.

3.4

Discussion

The urinary modulators tested in this study demonstrated enhancing, inhibitory,
neutral, and mixed effects on infectious crystal formation. While the pH level appears to
have an important role, an alkaline pH does not automatically equate to improved crystal
formation. Acids appear to have the most consistent ability to prevent infectious crystal
formation, except for sodium citrate, OPN and magdolate, which also had
inhibitory/preventative properties. Urinary acidification has been a proposed treatment
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approach for infectious stones,25 and these results further support that strategy. These
findings could be used to alter the treatment paradigm for patients with infectious kidney
stones.
The benefit of acids in preventing crystal formation could have been due to
preventing a rise in pH, active-site directed inhibition or mechanism directed inhibition of
urease, which has been documented previously.26 There are many compounds that have
been investigated in the past for urease inhibition including hydroxamic acids,
phosphoramidates, urea derivatives, quinone, polyphenols, quinolones, flavinoids and
heterocyclic compounds.27,28 For example, Svane et al. tested 71 compounds for urease
inhibiting activity with a variety of different mechanisms and identified 30 with
significant urease inhibition but etidronic acid was not one of them.29 This is very
surprising given that etidronic acid in our study yielded a pH less than 2 and
demonstrated complete crystal inhibition. There were several other acids tested that were
effective at inhibiting urease and some of the ones in our study may have overlapping
properties, but we cannot identify the mechanisms of inhibition in our study.
Some of the other compounds that were successful in inhibiting stone formation
potentially behave similar to acid in their mechanism. As previously mentioned, sulfate is
a titratable acid found in the kidney and is suspected to be the more dominant modulator
in zinc sulfate to prevent infectious crystal formation. Ibuprofen should also be
considered an acid because it’s chemical name of (R,S)-2-(4-isobutylphenyl)propionic
acid, however there can be a variety of chemical metabolites within the urine due to
methylation.30 Although it may act as an acid with promising results in our experiment,

101
these cannot be automatically applied clinically given the variability of urine metabolite
levels.
Magdolate is magnesium pidolate and magnesium is likely the predominant
modulating factor in this supplement. Evidence suggests that magnesium inhibits calcium
phosphate crystallization, but findings have not been consistent.10,14 Future work could
include investigating the correlation between 24-hour urinary magnesium levels and
stone formation/composition.
Citrate has been shown to inhibit urease-induced crystallization and delay the
onset of nucleation and growth of struvite crystals 8 and in our study we observed no
crystal formation whatsoever. While there may be hesitancy in implementing a clinical
therapy that might raise the urinary pH, the crystal inhibitory effects are compelling.
While the exact mechanism is not clear, there may be an indirect effect of increased
crystal inhibition with the use of citrate at higher pH levels.5 Therefore, citrate may be an
underutilized clinical treatment strategy in infectious stones.
Metformin in our experiment showed complete inhibition of crystal formation
which has been demonstrated with in vitro and in vivo models through antioxidant
effects.31 An important consideration, is that metformin does not undergo any metabolic
changes after being excreted into the urine,32 making our results of particular interest
clinically. Urinary citric acid has been shown to significantly increase in patients with
early type 2 diabetes treated with metformin out to 6 months of follow up.33 Although
this is unlikely to be the mechanism of action in our study, this coupled with the
aforementioned benefits of urinary citrate could be critical for those with diabetes and
infectious stones; and possibly even those without diabetes.
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OPN did not completely inhibit crystal formation, but delayed the onset of the
formation of crystals, slowed the reaction, and decreased the overall crystal volume quite
dramatically. This is consistent with other studies showing its inhibitory effect on
calcium oxalate and calcium phosphate crystal formation.9 The exact inhibitory
mechanism of calcium phosphate crystallization can vary depending on the
phosphorylation of OPN.34 There is limited evidence on struvite inhibition with OPN, and
given our findings, there may be no effect at all. There was a slow and gradual formation
of crystals that could represent the normal growth of struvite crystals only. Presumably,
we did not see the early phase growth of calcium phosphate crystallization which has
been shown to occur earlier in the urease-induced crystallization pathway.35 That being
said it, it may still be effective if it can be used while avoiding a pH rise above 7.0 and
subsequent struvite crystallization. The other added challenge with OPN is causing
upregulation in the kidney because it is mediated by inflammation and healing.
In vitro studies by Torzewska and Rozalski7, demonstrated that chondroitin
sulfate in Griffith’s artificial urine infected with Proteus mirabilis actually led to
increased struvite and calcium phosphate crystallization. A similar effect was seen in our
experiment with a greater AUC, but also a more robust reaction with urease leading to
rapid crystal formation. Vanillic acid at higher concentrations can be bactericidal for P.
mirabilis and can also inhibit urease at very low concentrations.7 The concentration in our
experiment was 10x lower, which may explain the difference in results. Sodium
bicarbonate enhanced crystal formation which is not surprising given its propensity to
dissociate in water and alkalinize the solution, thus providing better conditions for urease.
This is an important clinical comparison because some physicians will use sodium
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bicarbonate (baking soda) for urinary alkalinization and as we can see in our study the
effect in infectious stone formation is not the same with a citrate supplement.
Indole dramatically enhanced the effect on stone formation, but we are unsure of
the mechanism. Our lab has also demonstrated that indole can enhance calcium oxalate
crystal formation (unpublished data). Similarly, there is preliminary evidence associated
with P-Cresol causing increased calcium oxalate crystal formation in our lab. This
compound appears to have a mixed effect on crystal formation with early onset of crystal
development, but possible disruption via crystal aggregation and nucleation leading to a
slower doubling time and rate of crystal growth.
There were mixed effects with sodium pyrophosphate in our study which is
consistent with prior literature showing no influence on pH changes, urease activity,
bacterial growth and subsequent crystallization.7 Although it may have altered the initial
behaviour of the reaction, the end result overtime is a crystal yield similar to the controls
in our study. PASP was another modulator that had early onset of crystallization, but
slower growth over time. This supports prior studies showing that the mechanism of
action us by reducing aggregation.9,13 However, there does appear to be a dosedependent response with increasing concentrations leading to more inhibition36,37 so
increasing the dose in our experiment may lead to different results and could be explored
further in the future.
Compared to controls, heparin did not alter the reaction to any dramatic effect.
Prior studies have not shown any effect of heparin on urease-induced crystallization.11
We did not see a clear change in infectious stone formation with methionine in our study,
but this could be dose dependent on the amount of methionine used. One study noted that
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methionine gets converted into sulfate within the urine16 which may result in its actual
clinical benefit and not the methionine metabolite itself. In addition, many of these
studies use large amounts of methionine which may significantly raise the methionine or
sulfate levels in the urine and lead to a clinical benefit.
Overall, the strengths of our study are that the experimental conditions were
standardized and testing in artificial urine ensured that the effects demonstrated were
solely related to the modulator. We tested a large number of inhibitors, and the
concentrations of test substances were based on normal human urine concentrations
whenever possible. Limitations of this study include the effect of some of the urinary
modulators that may be concentration dependent, whereas we examined a single
concentration for each modulator. Additionally, we were unaware as to how the urinary
modulators would behave in the presence of bacteria, which could also be clinically
important.
Many urinary modulators were tested with our validated model and there were
results that were anticipated, but also exciting novel discoveries. This study provides
more evidence of the importance of urinary acidification to prevent infectious kidney
stone formation. The findings of significant infectious stone crystal inhibition with citrate
and OPN is noteworthy. Citrate is already clinically available as a well-known treatment
for calcium oxalate and uric acid stone prevention but has not been used in infectious
stone patients. Clinical evaluation of citrate in patients with infectious urinary stones
seems worthy of further investigation. Attempts to upregulate OPN for clinical effect has
yet to be successfully realized and would require further study. Another key finding in
this work was the somewhat counterintuitive role of urine pH and its impact on infectious
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stone formation. It has always been assumed that the higher the pH, the greater the
amount of infectious stone formation that occurs, however this is not always to case. For
example, both citrate and OPN were associated with similar or higher pH values yet
demonstrated effective inhibitory properties. This data calls into question some of our
long-held beliefs about how infectious stones form and in the next chapter, the
relationship between urinary pH, stone formation, urease, and bacteria will be further
explored.
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Chapter 4
4

Testing bacterial species for infectious stone formation in an
experimental model using artificial urine
Classically, urease producing bacteria have been associated with struvite and

calcium phosphate stone formation. Urease produced by certain bacterial species result in
the conversion of urea and water into ammonia and carbon dioxide which leads to a rise
in pH. The previous chapter demonstrated that an elevated pH does not always equate to
infectious stone development and an appropriate urinary milieu is required. In an effort to
expand our understanding of the relationship with bacteria and stone formation, we used
our experimental model to examine if crystals will originate from bacteria in the absence
of other urinary modulators.
A selection of the top 10 bacterial species associated with struvite stone formation
were used in our experimental model to permit their natural intracellular metabolic
pathways to develop crystals. Crystal growth curves, pH values, SEM/EDX and a
qualitative urease test were collected and analyzed. The results suggest that urease may
not be the only metabolic pathway involved in stone formation and calcium oxalate
crystal formation may be associated with bacterial activity.

4.1
4.1.1

Introduction

Urease producing bacteria and stone formation
The relationship between bacteria and urolithiasis is centred around urease-

splitting bacteria that were first discovered in 1901.1 It is estimated that over 200
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microorganisms have the ability to produce urease, but the activity varies between
species.2 Kalwasser et al. first demonstrated that nitrogen starvation can increase urease
activity, but certain strains like Proteus have urease activity regardless of the nitrogen
level.3 The ability of ureolytic bacteria to flourish in the human urinary tract is aided by
the large quantity of nitrogenous sources which allow for rapid development of
ammonia.2 One previous study isolated bacterial strains within kidney stones from
patients after SWL and none of the strains isolated were urease negative, regardless of the
stone type (non-infectious or infectious).4 The association between urease-producing
bacteria was taken a step further by McLean et al. by identifying that infectious stones are
only produced once the pH reaches 7-8.2 Despite the clear evidence showing the
connection between urease and infectious stones, there is still scientific skepticism on
whether or not this provides the complete story.

4.1.2

Alternative bacterial pathways leading to stone formation
In 1938, Hellström not only recognized the association of urease-splitting bacteria

and rapid stone formation, but hypothesized that UTIs likely played a role in all stone
types to varying degrees.5 This theory was not robustly investigated for many years,
however, more contemporary data shines a light on the importance of urinary
microbiomes. Urine has a natural microbiome that is distinctly different in stone formers
compared to healthy subjects.6 Additionally, urinary stones have demonstrated their own
microbiome7,8 and the connection between these microbiomes and stone composition
may hold the key to comprehending the stone-bacterial relationship. This recent area of
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research has continued to expand and supplementary concepts will be presented in the
following paragraphs to better portray the stone-bacterial relationship.
Reviewing the historical data on stone cultures shows anywhere from 15-70% of
stones are positive for bacteria further subdivision of this group into calcium oxalate
stones only, indicates positive stone cultures in 13-44% of case.9 A large multi-centre
clinical database of struvite stones documented the rates of bacterial strains within the
stones and the most prevalent were E. coli, Proteus and Enteroccocus.10 It is interesting
to note, that two bacteria (E. coli and Enterococcus) out of the top three are non-urease
producing bacteria in that study. Moreover, there were many other non-urease producing
bacteria identified in the stones, albeit with lesser frequency.
Nanobacteria is a term used to define the most diminutive bacteria identified in
bovine and human serum, which have been proposed to play a role in urinary stone
formation. Research has proposed that nanobacteria can lead to further crystal
propagation through either on cell induced injury11 or creation of a mineralized shell with
hydroxyapatite (calcium phosphate) crystals.12–15 Nanobacteria have also been identified
in Randall’s plaques, which have long been viewed as a nidus for crystal formation.16
Ultimately, it is hard to directly connect nanobacteria to crystal formation or whether they
are an incidental finding within the urine and kidney.
Bacterial mechanisms being involved in more than calcium phosphate and struvite
crystal formation would have substantial clinical implications for an appreciably larger
stone patient population. In a study by Dornbrier et al., 51 stones were analyzed with 16S
rRNA gene sequencing and 12 stones were found to have a predominant bacterial strain
present, which was compared to the expanded quantitative urine culture (EQUC) taken
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from the patients urine.17 Their results established that stone and urine bacteria were not
always congruent and that both calcium phosphate and calcium oxalate came from
patients with a negative urine culture.17
Barr-Beare et al. demonstrated increased calcium oxalate formation with
uropathogenic injury proceeding to increased cell injury, which has been shown to
increase crystal adherence and stone development.7,14 Individual bacterial components
provide crystals another surface to develop and bacterial flagellum appear to have the
greatest positive affect on calcium oxalate crystal aggregation and growth.18 It is possible
that just having additional physical structures to allow for improved crystal precipitation
is part of the explanation, but there are suspected bacterial metabolic pathways besides
urease involved.
Alternative bacterial metabolic pathways affecting kidney stone formation have
been identified from the gut microbiome and this knowledge has expanded our outlook
on the stone-bacterial relationship. Lactiplantibacillus plantarum N-1 appears to decrease
calcium oxalate crystal formation in the urine by regulating arginine levels and, also in
the same study, in vitro experiments proved that arginine exposure to renal epithelial HK2 cells prevents calcium oxalate adhesion.19 A case study looking at pathogenic
Kalamiella piersonii isolated from the urine of a struvite stone former showed without
any subunits for urease, bacteria can use amino acids for nitrogenous sources and elevate
the pH.20
Due to the growing uncertainty of the mechanism and total effect of stone
formation linked to bacteria, it is imperative to enhance our knowledge on the stonebacterial connection. We believe our high-throughput experimental model can shed some
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light on this complex relationship. This chapter analyzes the relationship between urease,
bacteria, and stone formation in an effort to validate our hypothesis that urease and nonurease producing bacteria will promote crystallization.

4.2

Materials and Methods

As this was an in vitro study, IRB approval from Western University was not
required.

4.2.1

Preparation of intracellular bacterial proteins
Bacterial strains tested for infectious stone formation were chosen based on a list

curated by the EDGE consortium on the rates of bacterial strains in struvite stones (Table
22).10

Table 22: List of bacterial strains tested for infectious stone formation with
experimental model.
Bacterial Strains
Proteus mirabilis 175A

Enterobacter cloacae
A4-RS-21

Proteus mirabilis 177A

Klebsiella oxytoca RCA+2

Escherichia coli UTI89
Staphylococcus aureus
USA300

Pseudomonas aeruginosa
PAO1
Citrobacter freundii
RCA+1

Klebsiella pneumoniae
RCA+18
Staphylococcus agalactiae
A3-MS-19
Enterococcus faecalis
A2-FV-11
Staphylococcus
epidermidis A2-FV-12

After the bacteria were streaked and incubated at 37C for 24 hours, one colony
was placed in 1.5 mL of Griffith’s artificial urine in a microcentrifuge tube.
Approximately 100 L of 100 m glass beads were added to the microcentrifuge tubes.
The bacteria were bead beat for 2 cycles of 1-minute intervals at 3,450
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oscillations/minute while being placed on ice for 1 minute in between. After bead
beating, the tubes were centrifuged at 20,817 x g for 5 minutes and the supernatant was
collected for the stone model.21

4.2.2 Running experimental model with bacteria
One mL supernatant was added to 9 mL Griffith’s artificial urine. Aliquots of 200
L were placed into a 96-well plate in technical triplicate. Plates were incubated at 37C
for 24 hours and absorbance was recorded every 5 minutes at 660 nm. Controls included
Griffith’s artificial urine with 0.1 U/mL urease and without urease were utilized. No Tris
buffer was added to this experiment. The Biotek Eon Microplate Spectrophotometer
(Winooski, Vermont, USA) and the Gen 5 v2.0 (Winooski, Vermont, USA) software
were used for analyzing the 96-well plate. Test tubes of the original mixture were placed
in an incubator at 37C at the same time for microscopy analysis. Upon completion of the
experiments at 24 hours, pH measurements were taken using a Mettler-Toledo FiveEasy
Plus pH meter F20 (Gerifensee, Switzerland). The bacteria that produced crystals had a
pH measured again after 48 hours of incubation at 37C.

4.2.3 Microscopic crystal evaluation and identification
Each of the original test tube solutions were filtered through 0.22 m vacuum
filtration system and the crystals were washed off the filter paper with deionized water.
The crystals were left suspended in water to allow for preparation for SEM/EDX. A
random sample of each solution was mounted on silica and examined with SEM
(Zeiss/Leo 1540XB FESEM, Oberkochen, Germany). Molecular composition of the

116
crystals was determined with EDX (Oxford Instruments X Max 50, England, United
Kingdom).

4.2.4 Qualitative urease test with Christensen’s agar
Christensen’s agar is formulated to detect and differentiate ureolytic and urea
degrading microorganisms. The ingredients required to make Christensen’s agar can be
found below in Table 23 and 24.22
Table 23: Initial ingredients for Christensen’s agar.22
Ingredient
Peptone
NaCl
Dextrose
KH2PO4
Phenol red
Agar
Distilled water

Amount
1 g/L
5 g/L
1 g/L
2 g/L
0.012 g/L
15 g/L
900 mL

The mixture in Table 23 was autoclaved for 15 minutes at 121C. The solution
was cooled down to 50-55C and the following ingredients were added under sterile
conditions:
Table 24: Final ingredients for Christensen’s agar after autoclaving.22
Ingredient
Amount
Urea
20 g/L
Distilled water
100 mL

After the components were adequately mixed, the solution was poured out into
individual agar plates to solidify and was stored at 4C.
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To determine if the bacteria produced urease, a single colony was suspended in 1
mL of PBS. A 10 L aliquot was pipetted onto the agar plate and the plates were
incubated at 37C for 48 hours.

4.2.5 Statistical analysis
Statistical analysis was carried out with RStudio version 2022.02.1 (Boston, MA,
USA) using the Growthcurver package version 0.3.1 to analyze crystal growth curves.23
All graphs and figures were created were accomplished using Prism – GraphPad version
9.3.1(San Diego, CA, USA).

4.3 Results
4.3.1

Urease results from Christensen’s agar
After 48 hours of incubation the bacterial strains on Christensen’s agar exhibited

strongly positive, weakly positive or negative for urease activity (Table 25). E. coli
UTI89, E. cloacae A4-RS-21, C. freundii RCA+1, S. agalactiae A3-MS-19, E. faecalis
A2-FV-11, and P. aeruginosa PAO1 were negative for urease activity. S. epidermidis
A2-FV-12, K. oxytoca RCA+2 and K. pneumoniae RCA+18 were weakly positive for
urease with only a ring around the bacterial colony turning pink (see Figure 18). S. aureus
USA300, P. mirabilis 175A and P. mirabilis 177A were strongly positive for urease
activity with the whole plate turning pink.
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Table 25: Bacterial strains incubated on Christensen’s agar for 48 hours.
Bacterial Species
Urease
E. coli UTI89
Negative
S. aureus USA300
Strongly positive
E. cloacae A4-RS-21
Negative
C. freundii RCA+1
Negative
S. agalactiae A3-MS-19
Negative
E. faecalis A2-FV-11
Negative
S. epidermidis A2-FV-12
Weakly positive
P. mirabilis 175A
Strongly positive
P. mirabilis 177A
Strongly positive
K. oxytoca RCA+2
Weakly positive
K. pneumoniae RCA+18
Weakly positive
P. aeruginosa PAO1
Negative
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Figure 18: Christensen’s agar after 48 hours for K. oxytoca RCA+2 (A), S.
aureus USA300 (B), K. pneumoniae RCA+18 (C), P. mirabilis 175A (D), S.
epidermidis A2-FV-12 (E), and P. mirabilis 177A (F).
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4.3.2

Bacterial species that did not produce crystals
The following bacterial strains did not produce any crystals: E. coli UTI89, S.

aureus USA300, E. cloacae A4-RS-21, C. freundii RCA+1, S. agalactiae A3-MS-19, E.
faecalis A2-FV-11, S. epidermidis A2-FV-12. When evaluating their pHs after 24 hours
(Table 26), the majority ranged from 5.80-6.00 except for S. epidermidis A2-FV-12,
which rose above 6.20 on all three biologic replicates.

Table 26: pH values after 24 hours for bacterial species that did not produce
crystals.
Bacterial Species
Biologic rep #1
Biologic rep #2
Biologic rep #3
E. coli UTI89
5.74
5.74
5.79
S. aureus USA300
5.81
5.82
5.81
E. cloacae A4-RS-21
6.02
5.99
5.99
C. freundii RCA+1
5.93
5.85
5.95
S. agalactiae A3-MS-19
5.83
5.88
5.84
E. faecalis A2-FV-11
5.77
5.77
5.83
S. epidermidis A2-FV-12
6.27
6.22
6.21

4.3.3

Bacteria species that produced crystals
The bacteria that did produce crystals included: P. mirabilis 175A, P. mirabilis

177A, K. oxytoca RCA+2, K. pneumoniae RCA+18, P. aeruginosa PAO1 (Figure 19).
These bacterial strains showed a rise in pH, but not to the same degree as the Griffith’s
with urease (Table 27). The bacterial strains associated with the greatest rise in pH were
both P. mirabilis strains, which also were close to reaching Griffith’s with urease
(pH=9.15). The only other bacteria that was able to reach a pH of 7.0 was K. pneumoniae
RCA+18 after 48 hours. Both P. mirabilis strains were adherent to the test tubes and
created a film with crystals that was not seen with any other strain.
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Table 27: pH values for bacterial species that produced crystals.
Bacteria
pH after 24 hours
pH after 48 hours
P. mirabilis 175A
7.92
8.99
P. mirabilis 177A
7.61
8.64
K. oxytoca RCA+2
6.20
6.82
K. pneumoniae RCA+18
6.27
7.02
P. aeruginosa PAO1
6.40
6.77
Griffith’s with urease
8.91
9.15
Griffith’s only
5.80
5.96

0.3

P. mirabilis 175A

OD 660

K. oxytoca RCA+2
0.2

P. mirabilis 177A
P. aeruginosa PAO1
K. pneumoniae RCA+18

0.1

0.0
0:00:00

6:00:00

12:00:00 18:00:00 24:00:00

Time
Figure 19: Crystal growth curves from crystal producing bacterial strains measured
by absorbance at a wavelength of 660 nm.

Both P. mirabilis strains were found to have the steepest curve and initiated the
reaction early, which is supported by their greater r values and lower t_mid values in
table 28. The Klebsiella species have a similar shaped curve, but K. oxytoca RCA+2 has
an r = 0.006 compared to K. penumoniae RCA+18 at r = 0.009. K. pneumoniae appears
to have the latest initiation of crystal growth of all bacteria and this coincides with it
having the lowest pH at 6.20 after 24 hours before it surpasses the pH of P. aeruginosa
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PAO1 at 48 hours. The empiric AUC for K. oxytoca RCA+2 is 52.27 which is second
highest. Pseudomonas aeruginosa PAO1 has a distinctive growth curve with early crystal
formation then reaching a plateau before increasing crystal formation again. Despite the
earlier crystal formation, P. aeruginosa PAO1 has the highest t_mid, (1382.57) and has
the greatest empiric AUC and growth capacity of all bacterial strains.

Table 28: Growth curve analysis for crystal producing bacterial strains.
Bacteria

l

n0

r

t_mid

t_gen

auc_l

auc_e

sigma

P. mirabilis
175A
0.146
0.000
0.008 1149.46 86.16
44.03
50.77
0.009
K. oxytoca
RCA+2
0.210
0.000
0.006 1239.54 122.62 52.47
52.27
0.002
P. mirabilis
177A
0.092
0.000
0.016 1061.18 44.57
34.75
34.69
0.004
P. aeruginosa
PAO1
0.333
0.002
0.004 1382.57 185.44 71.36
69.44
0.008
K. pneumoniae
RCA+18
0.112
0.000
0.009 1328.38 76.00
16.41
17.42
0.001
0
k = growth capacity, n = degrees of freedom, r = growth rate, t_mid = time to inflection
point, t_gen = doubling time, auc_l = logistic area under the curve, auc_e = empiric
area under the curve, sigma = goodness of fit.

The figures below depict crystals under light microscopy for bacteria that
produced crystals. Both Proteus strains are found in Figure 20 with P. mirabilis 175A
showing a large calcium phosphate crystal (“glass shard”) and less developed grouping of
possible calcium phosphate crystals with P. mirabilis 177A. The crystals shown in Figure
21 from K. oxytoca RCA+2, K. pneumoniae RCA+18 and P. aeruginosa PAO1 appear to
be more consistent with calcium phosphate crystals but do not have a well-defined
structure, therefore it is difficult to be certain based on these photographs what the true
composition is.
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A

B

C

D

Figure 20: P. mirabilis 175A crystals under brightfield light (A) and polarized light
(B) at 200x magnification. P. mirabilis 177A crystals under brightfield light (C) and
polarized light (D) at 200x magnification.

124

A

B

C

D

E

F

Figure 21: K. oxytoca RCA+2 crystals under brightfield light (A) and polarized light
(B) at 200x magnification. K. pneumoniae RCA+18 crystals under brightfield light
(C) and polarized light (D) at 200x magnification. P. aeruginosa PAO1 under
brightfield light (E) and polarized light (F) at 200x magnification.
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Figure 22A shows high urease productivity represented by a completely pink
Christensen’s agar with P. mirabilis 175A. The archetypal “coffin lid” appearance of
struvite crystals is found in Figure 22B with groupings of spherical crystals that is seen
with immature calcium phosphate crystallization. Figure 22C also depicts mixed
composition calcium phosphate and struvite crystals and this was confirmed with EDX
(Figure 22D) having large peaks for both phosphate and magnesium consistent with both
stone types.

Figure 22: A) Christensen’s agar with colony of P. mirabilis 175A. P. mirabilis 175A
crystals under SEM at 500x (B) and SEM (C) with EDX analysis (D).
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Results from Christensen’s agar show no urease activity with P. aeruginosa
PAO1 in Figure 23A, but it still produced calcium phosphate crystals (Figure 23C and
23D). The structure in Figure 23B is unique and there appears to be a filmy substance,
which may be representative of bacterial biofilm. There is no magnesium present in the
EDX analysis (Figure 23D), and the composition is consistent with calcium phosphate
only. The calcium phosphate crystals from P. aeruginosa PAO1 appear more cohesive
and mature regarding the structure compared to P. mirabilis 175A.

Figure 23: A) Christensen’s agar with colony of P. aeruginosa PAO1. P. aeruginosa
PAO1 crystals under SEM at 5000x (B) and SEM (C) with EDX analysis (D).
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K. oxytoca RCA+2 was weakly positive for urease activity (Figure 24A) and
rectangular crystals can be seen in the encircled area in Figure 24B. The crystal structure
in Figure 24C is distinctly different in the shape and architecture compared to the other
crystals shown. Analysis of crystal composition shows predominantly calcium (Ca),
carbon (C), and oxygen (O) with no magnesium and very little phosphate (Figure 24D).
This is most consistent with a calcium oxalate stone composition and this was not
attained in any other experimental run during this entire project.

A

C

D
B

Figure 24: A) Christensen’s agar with colony of K. oxytoca RCA+2. K. oxytoca
RCA+2 crystals under SEM at 2000x (B) and SEM (C) with EDX analysis (D).
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4.4

Discussion

In this chapter, we evaluated the ability of uropathogenic bacteria to promote
infectious stone crystal formation and we were able to identify bacterial strains that could
spontaneously create crystals in artificial urine. As anticipated, we observed that urease
producing bacterial strains such as P. mirabilis created an alkaline pH with calcium
phosphate and struvite crystal formation. Surprisingly, Klebsiella oxytoca RCA+2, which
was weakly urease positive, produced calcium oxalate crystals and did not increase the
pH comparably to Proteus strains. Furthermore, we were able to show calcium phosphate
crystal formation without urease activity with P. aeruginosa PAO1.
Only the P. mirabilis 175A and 177A strains had the urease activity to raise the
pH high enough to yield calcium phosphate and struvite crystal formation. Notably, S.
aureus USA300 was strongly positive for urease, but did not raise pH or produce crystals.
None of the other bacterial strains appeared to produce any struvite crystals, which is not
surprising given that struvite crystals will not form with a pH less than 7.0.24 The only
other bacterial strain to rise above a pH of 7 was Klebsiella pneumoniae RCA+18 after
48 hours, but reviewing the results of SEM/EDX and light microscopy only showed
calcium phosphate crystal composition. This could be related to the delayed growth and
the lack of rapid pH rise driven by a high urease activity favours calcium phosphate
rather than struvite crystal formation.
Identifying mixed stone compositions clinically with struvite and calcium
phosphate is quite common and this could be due to the slow rise of pH even
demonstrated with Proteus strains. The time required to raise the pH above 7.0 appears to
provide ample time for calcium phosphate to crystallize out of solution and could be the
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initial nidus that allows further stone growth. However, there are patients with a urine pH
above 7.0 that only produce calcium phosphate stones, and in these instances, there could
be two different physiochemical explanations. The first is that the magnesium to calcium
ratio is very low so limited available magnesium allows for predominantly calcium
phosphate crystallization. The opposite would be true for struvite stone formers having
low calcium and ample magnesium available. The second is that there is evidence to
show that UTIs can cause hypocitraturia which increases the risk of calcium stone
disease.25 This clinical scenario would be analogous to patients with dRTA who are
characteristically calcium phosphate stone formers.
Muted pH elevations and calcium phosphate crystal formation is supported by our
results from P. aeruginosa PAO1. Despite not producing a very high pH or any urease, P.
aeruginosa PAO1 was able to produce calcium phosphate crystals. Clinically we see
calcium phosphate stones at many different pH levels although its growth is improved
with higher pH levels as with struvite stones. Another notable finding in the SEM photos
is the unusual appearance of the crystals and the appearance of fluid around the structures
which could be a biofilm. Both P. mirabilis strains were adherent to the test tube possibly
from biofilm formation, and the ability to create a biofilm could play a role in improved
crystal formation, which will be discussed further below.
Although Klebsiella oxytoca RCA+2 was weakly positive for urease, it was able
to produce a crystal formation not previously seen with this model. With no magnesium
and minimal phosphate, the composition on EDX appears to be consistent with calcium
oxalate. A positive link with calcium oxalate crystallization and all bacteria including
non-urease producing bacteria has been established previously.26 Our results suggest that
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there may be bacterial intracellular proteins that are able to drive these crystal forming
reactions besides urease and the role of urease could may be less involved in the
pathogenesis of kidney stones than previously thought.
Initial pH measurements were not taken for the experiments, however the
experiments with non-crystal producing bacteria the pH ranged from 5.80-6.00, which is
akin to our control of Griffith’s artificial urine (pH ~ 5.80). The only bacterial strain that
behaved differently was S. epidermidis A2-FV-12 which had a pH of greater than 6.20,
but given it produced urease, we would expect a pH rise. Despite S. epidermidis A2-FV12 having a similar pH to both Klebsiella species after 24 hours, S. epidermidis A2-FV12 was unable to produce crystals. As we have seen with OPN and citrate modulation, a
high urinary does not guarantee crystal formation and other factors are likely at play.
The findings from this study suggest that there are other factors involved in stone
development in association with bacteria besides urease. The Proteus strains most likely
used urease to elevate the pH in the experiment high enough to see both calcium
phosphate and struvite crystal formation. There are possibly non-urease proteins that use
urea (or other nitrogen sources) to raise pH and lead to crystal formation, which could
explain our findings from P. aeruginosa PAO1. Both Klebsiella species had weakly
positive urease activity, but it is not clear how this led to crystal formation especially
since K. oxytoca RCA+2 formed calcium oxalate crystals.
The presence of bacterial biofilm could be important for two reasons, the biofilm
allows concentration and localized activity of urease or the matrix acting as its own nidus
for crystal growth.27 A study by Whitchurch et al. discovered that extracellular DNA is
required for P. aeruginosa biofilm and this could be similar with other bacteria.28
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Therefore, just having the intracellular components in our experiments may have allowed
for a biofilm/matrix to form to further enhance the crystal production, specifically with
the Proteus strains and P. aeruginosa PAO1.
The lack of a pathophysiologic understanding in infectious urinary stones has led
to a paucity of preventative strategies with a proven track record of clinical benefit.
Antimicrobial agents cannot fully penetrate the crystal lattices of the stone to treat all
bacteria, so its benefit is limited once a stone has formed.29 Antimicrobial stewardship is
vitally important because there are long term-risks with prolonged antibiotic use
including bacterial resistance and secondary infections.29 Acetohydroxamic acid is a
urease inhibitor that has shown success in small studies but has a significant side effect
profile that has prevented its widespread use. Its clinical relevancy is nullified by nonurease producing bacteria forming stones and only exposes patients to harm. With a
better understanding of the mechanisms behind infectious stone formation, more reliable
prevention of their occurrence may lead to improvement in patient care and quality of
life.
The strengths of this study are that the bacteria used their own intracellular
proteins to react with the artificial urine. We tested the most common bacteria associated
with struvite stone which make the findings clinically relevant. Limitations of this study
are the bead beating protocol may not have been adequate to disrupt the cellular wall. S.
aureus is an example of this where it had high urease activity but did not create any
crystals owing to the notoriously hard cellular wall to break in this bacterium.
Furthermore, protein levels were not standardized across the experiment that could skew
our growth curves. Christensen’s agar is a qualitative test and may not be sensitive
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enough to pick up low or optional urease producing bacteria. Two strategies to improve
the sensitivity of Christensen’s agar would be eliminating all non-urea nitrogenous
sources and lengthening the incubation period up to 96 hours.4
The results of this experiment suggest that infectious stone formation is a more
intricate clinical entity than previously understood. We were able to show that urease
activity is not directly related to calcium phosphate formation, but high urease activity
does appear necessary to raise the pH above 7.0 to allow for struvite formation. The most
surprising finding is calcium oxalate crystals forming with K. oxytoca, which supports the
theory that bacteria may be involved in more stone types than calcium phosphate and
struvite. Further investigation into these bacterial species to identify the exact
intracellular proteins involved in the development of urinary crystals is required.
Enhancing our working knowledge of the bacterial-stone relationship could lead to
improved clinical approaches to minimize infectious and calcium oxalate stone
recurrence.
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Appendices
Appendix A: R code for “Growth Curver Package”
# Script to run GrowthCurver on Infectious Crystal Formation
# Load library
library(growthcurver)
# Load data
data1 <- read.csv("input_filename.csv", header = TRUE, sep = ",", quote = "\"", fill =
TRUE, comment.char = "")
data1$Time <- seq(from = 0, to = 1440, by = 5)
# Run GrowthCurver this will normalize each well to the lowest value
gc_out <- SummarizeGrowthByPlate(plate = data1, bg_correct = "min", plot_fit = TRUE,
plot_file = "trial_1_gc_plots.pdf")
# Look for notes about bad fit (dont want any of these)
gc_out$note != ""
# Print the CSV file with the data
write.csv(gc_out, file = "output_filename.csv", row.names=FALSE)
##### Legend
# k --> carrying capacity
# n0 --> initial population size
# r --> growth rate r
# t_mid --> time at which the population density reaches 1/2K (which occurs at the
inflection point)
# t_gen --> fastest possible generation time (also called the doubling time)
# auc_l --> area under the logistic curve obtained by taking the integral of the logistic
equation
# auc_e --> empirical area under the curve which is obtained by summing up the area
under the experimental curve from the measurements in the input data
# sigma --> smaller sigma values indicate a better fit
# note --> to find poor fitting values
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Appendix B: Crystal growth curves of Griffith’s artificial urine with varying urease
concentrations measured by absorbance at a wavelength of 660 nm.

Griffith's Artificial Urine

OD 660

1.0

Urease Concentration
0.2 U/m

0.8

0.175 U/m

0.6

0.15 U/m
0.125 U/ml

0.4

0.1 U/ml

0.2

0.075 U/ml

0.0
0:00:00

0.05 U/ml
1:00:00

2:00:00

Time

3:00:00

4:00:00

0 U/ml
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